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Summary 
While endothelial cell (EC) function is influenced by mitochondrial metabolism, 
the role of mitochondrial dynamics in angiogenesis, the formation of new blood 
vessels from existing vasculature, is unknown. Here we show that the inner 
mitochondrial membrane mitochondrial fusion protein Optic Atrophy 1 (OPA1) is 
required for angiogenesis. In response to angiogenic stimuli, OPA1 levels rapidly 
increase to limit nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB) signaling, ultimately allowing angiogenic genes expression and 
angiogenesis. Endothelial Opa1 is indeed required in an NFκB-dependent 
pathway essential for developmental and tumor angiogenesis, impacting on 
tumor growth and metastatization. A first-in-class small molecule specific OPA1 
inhibitor confirms that EC Opa1 can be pharmacologically targeted to curtail 
tumor growth. Our data identify Opa1 as a crucial component of physiological 
and tumor angiogenesis. 
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Introduction 
Angiogenesis, the new blood vessel formation from preexisting vasculature, is crucial 
for embryogenesis, tissue healing, ovulation and placental vascularization (Carmeliet, 
2005a). In response to pro-angiogenic stimuli, endothelial cells (ECs) specialize into 
different subtypes, each performing specific functions: tip cells, highly responsive to 
vascular endothelial growth factor (VEGF), extend filopodia at the forefront of the 
vascular branch and guide its migration but are poorly proliferative; stalk cells, in which 
VEGF receptor 2 (VEGFR2) signaling is suppressed, are located behind the tip cells 
and proliferate to extend the vascular branch (De Smet et al., 2009; Gerhardt et al., 
2003; Potente et al., 2011). Once the vessel is formed and perfused, ECs become 
quiescent phalanx cells. Not surprisingly, such a complex specialization process is 
coordinated by a plethora of signaling factors including paracrine and autocrine factors, 
shear stress and even metabolic cues (Carmeliet, 2005b; Gerhardt et al., 2003; Phng 
and Gerhardt, 2009). Despite that angiogenesis is an energy-consuming process and 
that ECs have immediate access to blood oxygen, their metabolism is largely glycolytic 
(Cruys et al., 2016; Dobrina and Rossi, 1983; Krutzfeldt et al., 1990), impacting on 
angiogenesis in vivo (Dobrina and Rossi, 1983; Harjes et al., 2012; Harjes et al., 2016; 
Zecchin et al., 2017). A corollary of the glycolytic nature of ECs metabolism is that our 
knowledge on the role of mitochondria in angiogenesis is scant: angiogenic stimulation 
increases mitochondrial respiration (Guo et al., 2017) and mitochondria derived 
metabolites are essential to fuel cell proliferation and to keep signaling cascades in 
check. Indeed, PGC1α, the master regulator of mitochondrial biogenesis, is induced in 
ECs by several proangiogenic factor such as VEGF, hypoxia or caloric restriction. The 
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PGC1α-dependent mitochondrial biogenesis is a protective mechanism of ECs against 
oxidative stress (Afolayan et al., 2016; Patten and Arany, 2012; Valle et al., 2005). 
However, function of mitochondria extends far beyond their role in energy conversion as 
they participate in complex cellular processes: apoptosis, immune signaling, even 
differentiation (Pernas and Scorrano, 2016).  
Mitochondrial function is dynamically controlled by mitochondrial shape and 
morphology, depending on the balance between fusion and fission processes (Pernas 
and Scorrano, 2016). Fission occurs upon the recruitment of dynamin-related protein 1 
(DRP1) on the outer mitochondrial membrane (OMM), where it binds to its adaptors, 
fission 1 (Fis1), mitochondrial fission factor (MFF), and mitochondrial division (Mid) 49 
and 51. Mitochondrial fusion is controlled by mitofusins (MFN) 1 and 2 in the OMM and 
by optic atrophy protein 1 (OPA1) in the inner mitochondrial membrane (IMM) (Chen et 
al., 2003; Cipolat et al., 2004). Independently from its role in mitochondrial fusion, OPA1 
regulates apoptosis by participating in cristae junction formation and maintenance 
(Cipolat et al., 2006; Frezza et al., 2006). In addition, OPA1 stabilizes respiratory chain 
super-complexes, controlling mitochondrial respiratory activity and mitochondria-
dependent cell proliferation (Cogliati et al., 2013). Because mitochondrial shape and 
dynamics can be modulated by cellular cues and are intimately linked to the functions of 
this organelle, cells can use them to regulate integrated cellular processes, like 
response to intracellular pathogens (Pernas et al., 2018) or cardiomyocyte 
differentiation, where mitochondrial fusion is required to properly tune gene expression 
(Kasahara et al., 2013).  
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To understand if mitochondria play a role in angiogenesis, we identify in publicly 
available datasets of gene profiling during angiogenesis transcriptional changes of key 
mitochondrial genes and in models of angiogenic stimulation EC mitochondrial 
elongation, associated with a rapid increase in Opa1 levels. By combining imaging, 
genetics, gene expression profiling as well as a small molecule first in kind Opa1 
specific inhibitor, we show that Opa1 is required for angiogenesis and for tumor growth 
and metastatization, by impinging on NFκB activity and on angiogenic gene expression. 
Our data reveal a previously unappreciated role for Opa1 in the coordination of the 
angiogenic process. 
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Results 
Angiogenic stimuli increase ECs Opa1 levels and mitochondrial length.  
To investigate whether changes in mitochondrial shape are part of the angiogenic 
program, we took advantage of kdrl:mCherry/kdrl-mls:GFP transgenic D. rerio where 
blood vessel specifically express mitochondria -targeted GFP (mtGFP). Live imaging of 
these transgenic embryos showed elongated mitochondria in tip ECs (Fig. 1A). We 
recapitulated this finding in vivo in the mouse. We compared mitochondrial shape in 
different EC subtypes in the Endo-mitoGFP mouse that expresses mtGFP specifically in 
ECs (Pickles et al., 2013). Confocal imaging of live retinal mounts showed that 
mitochondria were fragmented in quiescent adult retinal phalanx ECs and in neonatal 
proliferating stalk ECs, tubular in the angiogenic active tip cells (Fig. 1B-E). Finally, 
mitochondria elongated also in a cellular model of angiogenesis, when Human Umbilical 
Vein Endothelial Cells (HUVEC) were exposed to different proangiogenic stimuli (VEGF, 
Fig. 1F,G, or bFGF and tumor conditioned medium, not shown).  
To gain insight into the mechanism leading to mitochondrial elongation during 
angiogenesis, we resorted to the publicly available ANGIOGENES database of RNA 
sequencing during angiogenesis (http://angiogenes.uni-frankfurt.de). Even if replicated 
measurements for most genes in this dataset are lacking, we could operatively define 
differentially expressed genes (DEGs) by using an in-house generated statistical 
approximation method. We therefore computed and ranked the transcriptional changes 
of 20,185 human genes during VEGF treatment of HUVEC and we used this dataset to 
perform pathway analysis by SPIA (Tarca et al., 2009). By using Graphite, we collected 
human pathways from seven different databases (BioCarta, HumanCyc, KEGG, 
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PANTHER, PharmGKB, Reactome and SMPDB) and we ran the SPIA algorithm over all 
the resulting networks (Sales et al., 2012). Intriguingly, in addition to the expected 
pathways known to participate in angiogenesis, we retrieved several ones involving 
mitochondria (Supplementary Dataset 1). We therefore intersected the list of 
transcriptionally altered genes with the Human MitoCarta 2.0 database 
(https://www.broadinstitute.org/files/shared/metabolism/mitocarta/human.mitocarta2.0.ht
ml), identifying 994 mitochondrial genes whose transcription was dynamically 
modulated during VEGF stimulation of HUVEC. A heat map of Pearson-correlation 
clustered gene expression revealed that, among the fusion genes, only OPA1 was 
upregulated early (Fig. 1H). Back to the wet lab, we confirmed by real time PCR that in 
VEGF-stimulated HUVECs OPA1 mRNA levels rapidly increased, whereas no changes 
in MFN1 and 2 expression were observed (Fig. 1I). Similarly, Opa1 protein levels 
increased ~3 fold 2h following VEGF treatment (Fig. 1J), suggesting that the observed 
mitochondrial elongation could be a consequence of the increased OPA1 expression.  
To understand if also in vivo Opa1 levels correlated with the elongated mitochondrial 
morphology observed in angiogenic active EC subtypes, we turned to the mouse retina 
model of physiological angiogenesis. Mouse retina is avascular at birth and blood 
vessels progressively sprout from the center towards the periphery until postnatal day 7 
(P7). Simultaneously, blood vessels from the superficial (L1) vascular plexus start to 
sprout inside the retina to form the deeper plexus (L3). L1 contains stalk and tip cells 
from P2 to P6; at P8, L1 ECs become phalanx cells and L3 ECs are angiogenic (Fig. 
1K) (Gerhardt et al., 2003; Stahl et al., 2010). In line with our in vitro data, we retrieved 
high OPA1 immunoreactivity in L1 tip cells at P4 (Fig. 1L). Conversely, at P11 the 
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angiogenic inactive L1 phalanx cells were barely immunoreactive for OPA1, as opposed 
to the strong OPA1 staining observed in the L3 angiogenic active ECs (Fig. 1M). Thus, 
Opa1 levels are higher and mitochondria are elongated in ECs undergoing angiogenic 
stimulation in vitro and in vivo.  
 
Opa1 is required for angiogenesis in vitro and in vivo. 
We next tested the physiological significance of the observed Opa1 levels increase 
triggered by angiogenic stimulation. First, we efficiently silenced OPA1 by siRNA in 
HUVECs, obtaining the expected mitochondrial fragmentation (Supplementary Fig. 
S1A-C). While OPA1-silenced cells remained viable throughout the experiment 
(Supplementary Fig. S1D), all the measured angiogenic parameters: migration 
(Supplementary Fig. S1E-F), proliferation (Supplementary Fig. S1G) and 
tubulogenesis (Supplementary Fig. S1H-I) were curtailed. To determine whether these 
effects were specific for OPA1 deletion or generically caused by the perturbation of 
mitochondrial fusion, we efficiently silenced MFN1 or MFN2 in HUVECs, causing again 
the expected mitochondrial fragmentation (Supplementary Fig. S1J-L). Nevertheless, 
while MFNs silencing induces a significant degree of ECs death (Supplementary Fig. 
S1M), all the angiogenic parameters of migration (Supplementary Fig. S1N-O), 
proliferation (Supplementary Fig. S1P) or tubulogenesis (Supplementary Fig. S1Q-R) 
were unaffected.  
Comforted by these results, we decided to investigate if Opa1 influenced angiogenesis 
in vivo. First, we measured if angiogenesis was stimulated by increased Opa1 levels in 
the Opa1tg mice (Varanita et al., 2015). OPA1 levels were slightly higher in Opa1tg 
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primary mouse pulmonary endothelial cells (MPECs) that after two rounds of 
purification, the isolated MPECs expressed the EC markers VE-Cadherin, VEGFR2 and 
Endothelial specific molecule 1 (ESM1), confirming their endothelial identity 
(Supplementary Fig. 2A,B). Isolectin-B4 staining of retinal vessels of Opa1tg P5 pups 
revealed a small but significant increase in the radial expansion of the retinal vascular 
plexus (Fig. 2A-B). Next, we decided to generate a mouse model of endothelial-specific 
Opa1 ablation. Opa1f/f mice were crossed with Tg(Tek-cre) 2352Rwng mice expressing 
the Cre recombinase under the Tie2 promoter in ECs, generating EC Opa1 knockout 
animals (Opa1ΔEC/ΔEC). Opa1ΔEC/ΔEC mice died during embryogenesis, but we could 
analyze heterozygous Opa1ΔEC/+ mice that were born in normal mendelian ratios and 
developed normally. We first evaluated the angiogenic parameters in primary MPECs 
from neonatal Opa1+/ΔEC mice. As expected, Opa1 protein levels were reduced by 50% 
in purified Opa1ΔEC/+ MPECs (Supplementary Fig. 2C), and migration (Fig. 2C-D) as 
well as proliferation (Fig. 2E) were reduced, in line with what observed upon OPA1 
silencing in HUVEC. While these heterozygous Opa1 MPEC were useful to confirm the 
specificity of the antiangiogenic effects observed upon OPA1 silencing in HUVEC, we 
were still uncertain of whether angiogenesis in vivo required Opa1. Interestingly, 
isolectin-B4 staining of retinal vessels of Opa1+/ΔEC pups at P4 revealed that ECs loss of 
OPA1 reduced radial expansion of the vascular plexus (Fig. 2F-G), diminished the 
number of vascular branch points (Fig. 2H-I), reduced the number of tip cells (Fig. 2J-
K). In addition, Isolectin-B4 staining of retinal vessels of Opa1+/ΔEC pups at P6 revealed 
that EC loss of OPA1 slightly reduced the venous branching (Supplementary Fig. 2D-
E). Retinal veins can be theoretically assigned to three different regions: proximal (Vp, 
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located close to the optic nerve), central (Vc, in the middle of the plexus) and distal 
veins (Vd), responsible for the sprouting (Supplementary Fig. 2F). The slight venous 
branching reduction observed in Opa1+/ΔEC pups was caused only by the decrease in Vd 
branching. Conversely, Vc and Vp branching were not affected (Supplementary Fig. 
2G) like the arteriovenous patterning and the arterial branching (Supplementary Fig. 
2H-I).  
To investigate the effect of complete Opa1 ablation in vivo and to avoid the potential 
issues of Opa1 deletion in hematopoietic cells caused by the Tie2-Cre system (Kisanuki 
et al., 2001), we generated an inducible endothelial knockout model for Opa1 (Opa1iΔEC) 
by crossing Opa1f/f with Cdh5(PAC)-CreERT2 mice, expressing the Cre recombinase 
under the tamoxifen-inducible Vascular Endothelial (VE) cadherin promoter (Wang et 
al., 2010). Acute Opa1 ablation was induced by a daily Tamoxifen injection from P1-P3, 
resulting in a significant Opa1 mRNA reduction at P5 in MPECs from Opa1iΔEC pups 
(Supplementary Fig. 2J). Moreover, the efficiency of the tamoxifen induced Opa1 
deletion was also confirmed by OPA1 immunostaining in P6 retinal blood vessels 
(Supplementary Fig. 2K). Acute EC Opa1 ablation curtailed radial vascular plexus 
expansion (Fig. 2L-M), vascular branch points (Fig. 2N-O), tip cells (Fig. 2P-Q), and 
slightly reduced venous branching (Supplementary Fig. 2L-M) because of the 
decrease in Vd branching, without any effect on Vc and Vp branching (Supplementary 
Fig. 2N-O) or arteriovenous patterning and arterial branching (Supplementary Fig. 2P-
Q). These data indicate that Opa1 is essential for angiogenesis in vivo.  
To explore the functional relevance of in vivo Opa1 ablation, we turned to fli1a:EGFP 
zebrafish embryos expressing GFP in ECs and analyzed only viable embryos without 
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major developmental alterations. Opa1-specific morpholino injected-embryos showed a 
reduction in Opa1 protein level 24 hours post-fertilization (hpf) (Fig. 2R), leading to 
mitochondrial fragmentation in intersomitic vessels (ISVs) (Fig. 2S-T). Functionally, the 
lack of Opa1 altered ISV sprouting, reducing the number and length of filopodia (Fig. 
2U-V). To determine whether these effects were specific for OPA1 deletion or 
generically caused by the perturbation of mitochondrial fusion, we generated an 
inducible endothelial knockout model for Mfn1 (Mfn1iΔEC) by crossing Mfn1f/f with Pdgfb-
iCreER mice (Claxton et al., 2008). In line with the in vitro data, acute EC Mfn1 ablation 
does not affect radial vascular plexus expansion (Supplementary Fig 2R-S), vascular 
branch points (Supplementary Fig 2T-U) or tip cells (Supplementary Fig 2V-W). 
Finally, the effect of EC Opa1 ablation was confirmed in a further mouse model of 
angiogenesis, the Matrigel plug assay. Vessel growth into Matrigel plugs (assayed by 
measuring hemoglobin content) was reduced in Opa1+/ΔEC mice (Fig. 2W-X).  
Our results indicated that in the absence of Opa1, angiogenesis was curtailed. 
However, they did not prove that Opa1 induction was required to modulate 
angiogenesis. To address this question, we first performed a small pharmacological 
screening to identify which pathway downstream of VEGF was responsible for Opa1 
upregulation during angiogenesis. Inhibitors of ERK (PD98059), JAK/STAT (AG490) 
(Seo et al., 2009) and STAT3 (LLL12) (Lin et al., 2010) but not of PI3K/AKT pathways 
(wortmannin) curtailed OPA1 upregulation and mitochondrial elongation downstream 
VEGF activation (Fig. 3A and Supplementary Fig. 3A-C). These data indicate that 
VEGF increases OPA1 levels via the MAPK and STAT3 pathways. Because inhibitors 
of these pathways interfere with multiple aspects of angiogenesis, they cannot be used 
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to directly test if Opa1 induction was required for angiogenesis. We therefore devised a 
genetic system where we could in principle specifically prevent the increase of Opa1 
downstream of VEGF. We generated Opa1f/f::Opa1tg mice by crossing Opa1tg (Varanita 
et al., 2015) with Opa1f/f mice (Cogliati et al., 2013). We isolated Opa1f/f::Opa1tg MPEC 
and we infected them with Cre adenoviruses to delete genomic, but not transgenic 
expression of Opa1 (Supplementary Fig.3D). As expected, Opa1 mRNA expression 
levels were stable following Cre delivery in VEGF treated Opa1f/f::Opa1tg MPEC 
because the genomic locus responsible for it was excised (Supplementary Fig.3E). 
Cre-adenovirus infection of MPEC did not affect VEGF signaling per se, measured by 
following VEGF-induced ERK phosphorylation (Fig. 3B). Conversely, it curtailed OPA1 
protein increase (Fig. 3B), mitochondrial elongation (Supplementary Fig. 3F-G), and 
strikingly the two key parameters of angiogenesis cell migration and proliferation (Fig. 
3C-D). Taken together, these results place the observed increase in Opa1 as a required 
component of angiogenesis in vitro, ex vivo and in vivo.  
 
EC Opa1 is required for expression of angiogenic genes. 
We next wished to understand the molecular mechanism by which Opa1 controls 
angiogenesis. Cell death could explain the observed antiangiogenic phenotype of Opa1 
ablation, but because HUVECs Opa1 ablation did not induce it (Supplementary Fig. 
1D), we investigated if the vascular defects were caused by an alteration of 
mitochondrial function. However, Opa1 ablation in vitro in HUVEC and in vivo in MPEC 
did not affect ATP levels (Fig. 3E), or HUVEC respiration and mitochondrial membrane 
potential (Supplementary Fig. 3H,I), leaving the mechanism by which Opa1 controls 
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angiogenesis unexplained. We therefore performed unbiased deep sequencing to 
investigate if gene expression was rewired by Opa1 deletion. The comparison of RNA 
sequencing (RNAseq) data obtained from triplicate analyses of control and Opa1-
ablated HUVECs indicated that 1226 genes out of a total of 16427 genes with 
measured expression were differentially expressed [fold change (FC) threshold=0.6; 
FDR=0.05; Fig. 3F; extended dataset 2; GEO: accession #GSE122042]. Interestingly, 
among the downregulated genes we retrieved, as expected, OPA1 (FC=-1.32; 
FDR=2.39x10-39), but also a number of genes involved in the promotion of angiogenesis 
like SERPIND1 (FC=-1.52; FDR=1x10-19); SERPINH1 (FC=-0.77; FDR=9x10-4); ID1 
(FC=-0.9; FDR=0.005); PDGFC (FC=-0.64; FDR=3x10-6) (Ikeda et al., 2012; Li et al., 
2005; Qiu et al., 2011; Wu et al., 2016). Conversely, among the upregulated genes we 
found inhibitors of angiogenesis like Flt1, that interferes with the VEGF pathway (Ambati 
et al., 2006; Roberts et al., 2004) (Fig. 3F). We therefore tested by quantitative PCR 
(qPCR) the response of a panel of genes involved in angiogenesis to OPA1 silencing in 
HUVEC. Remarkably, all pro-angiogenic genes tested were reduced, except for EPHb4, 
the venous markers involved in the arteriovenous patterning (Adams, 2003; Wilkinson, 
2001), whereas FLT1 levels were increased (Fig. 3G). Thus, OPA1 silencing skews 
gene expression in HUVEC towards an anti-angiogenic state.  
To get further insights into how an inner mitochondrial membrane protein can regulate 
gene expression, we used IpathwayTM (Advaita) analysis to represent enriched signaling 
pathways that might account for the observed changes in gene expression profile upon 
OPA1 silencing. Interestingly, a handful of apparently unrelated pathways were over-
represented (Fig. 3H); at a closer look, these pathways shared a common trait 
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represented by the activation of NFκB. Indeed, reads for mRNAs of NFκB activators and 
target genes increased, while those for NFκB inhibitors were decreased in OPA1-
ablated HUVECs (Fig. 3I). We therefore measured if these transcriptional changes were 
mirrored by differences in NFκB activity. NFκB catalytic P65 subunit activity was 
increased in OPA1-ablated ECs, as judged by a specific NFκB ELISA (Fig. 3J). 
Comforted by the fact that OPA1 but not the other fusion genes MFN1 or MFN2, 
controlled NFκB in ECs (Fig. 3J), we verified if OPA1 silencing interfered with the 
normal changes in NFκB activity during angiogenic stimulation. While NFκB activity 
declined rapidly after VEGF treatment in control HUVEC, this decrease was absent in 
OPA1-ablated HUVECs (Fig. 3K).  
 
Opa1 regulates NFκB and angiogenesis by impinging on Ca2+ signaling.  
NFκB is tightly controlled by its endogenous inhibitor IκBα whose degradation by the 
ubiquitin-proteasome system allows NFκB nuclear translocation and transcriptional 
activity (Kanarek et al., 2010). Interestingly, OPA1 silencing led to IκBα degradation, as 
shown by specific immunoblotting (Fig. 3L). We next wished to ascertain which 
upstream pathway [AKT/mTOR/Raptor, Ca2+ signaling, ERK (Dan et al., 2008; Jiang et 
al., 2004; Lilienbaum and Israel, 2003)] connected OPA1 silencing to IκBα degradation. 
Because in OPA1-deficient HUVEC ERK and AKT phosphorylation, as well as mTOR 
targets were unaffected (Supplementary Fig. 3J and not shown), we turned our 
attention to Ca2+ signaling that can be modulated by Opa1 (Fulop et al., 2011). 
Interestingly, Opa1 is retrieved among the interactors of MICU1 (Tomar et al., 2019), a 
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crucial regulator of the mitochondrial Ca2+ uniporter (MCU) that mediates Ca2+ uptake in 
mitochondria (Csordas et al., 2013). 
We first addressed whether deletion of Opa1 impacted on MICU1-containing 
complexes. Blue Native gel electrophoresis (BNGE) indicated that upon acute deletion 
of Opa1 in MEFs, total MICU1 levels where unaffected, but levels of a ~720 KDa 
MICU1-MCU-Opa1-containing complex were decreased (Fig 3M). Functionally, this 
remodeling of the MCU complex organization upon Opa1 deletion was mirrored by 
changes in cytosolic Ca2+ levels, which were increased upon Opa1, and as expected 
upon Micu1 ablation in HUVECs. Simultaneous Opa1 and Micu1 silencing did not lead 
to a further increase in cytosolic Ca2+, confirming that Opa1 and Micu1 not only interact, 
but also lie in the same pathway modulating Ca2+ levels (Fig. 3N). Several experiments 
also indicated that MICU1 and OPA1 are placed in the same pathway controlling NFkB 
activity and angiogenesis. First, like Opa1, also MICU1 silencing in HUVECs reduced 
Supplementary Fig. 3K). Second, MICU1 silencing inhibited HUVEC 
migration, tubulogenesis and proliferation (Supplementary Fig. 3L-Q). Third, we did 
not measure any additive effects of the simultaneous OPA1 and MICU1 ablation on 
IκBα decrease (Supplementary Fig. 3K) or angiogenesis (Supplementary Fig. 3L-Q). 
Altogether, these data support a role for the Opa1-MICU1 axis in the regulation of Ca2+ 
levels and NFκB activity. We therefore wished to understand if the defects in 
angiogenesis caused by Opa1 ablation were Ca2+-dependent. In Opa1-silenced 
HUVECs, the cell-permeant chelator BAPTA-AM (Tsien, 1980) could stabilize IκBα (Fig. 
3O), and curtail the NFκB hyperactivation (Fig. 3P) as well as the defective migration 
(Fig. 3Q-R). In vivo, intraocular injection of BAPTA-AM corrected all the retinal vascular 
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defects (radial expansion, branch points, total venous branching and distal branching 
points) recorded in Opa1+/ΔEC pups (Fig. 3S-U). Thus, Opa1 modulates angiogenesis by 
regulating cytosolic Ca2+ levels. 
 
Opa1 regulates angiogenesis via NFκB. 
To investigate whether the observed NFκB hyperactivation caused the antiangiogenic 
effect of Opa1 ablation, we first pharmacologically blocked NFκB. The well-
characterized IκBα kinase inhibitor BAY11-7082 (Pierce et al., 1997) did not reduce 
basal HUVEC NFκB activity, but it normalized NFκB activation and HUVEC migration 
recorded upon OPA1 silencing (Supplementary Fig. 4A-B). Comforted by these 
results, we decided to downregulate by siRNA the P65 subunit of NFκB 
(Supplementary Fig. 4C). Similar to what observed upon pharmacological inhibition, 
P65 siRNA normalized migration and tubulogenesis in HUVEC where OPA1 was 
simultaneously silenced (Fig. 4A-E). To further verify whether NFκB was required for 
the vascular defects caused by Opa1 ablation, we generated a mouse model of 
endothelial-specific Opa1 and P65 ablation. The Opa1+/ΔEC mice were crossed with 
P65f/f (Algul et al., 2007) to generate P65,Opa1+/ΔEC mice (Supplementary Fig. 4D-F). 
As expected, Opa1 and p65 protein levels were reduced in MPECs isolated from the 
double mutant mouse (Supplementary Fig. 4G). Notably, all retinal vascular defects 
(radial expansion, branch points, total venous branching and distal branching points) 
recorded in Opa1+/ΔEC mice were rescued in P65,Opa1+/ΔEC mice (Fig. 4F-J). Consistent 
with the in vitro and mouse data, BAY11-7082 inhibited NFκB activation caused by opa1 
ablation also in zebrafish (without affecting the basal NFκB activity, Supplementary 
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Fig. 4H) and restored the ISVs sprouting defects observed in opa1-morphant embryos 
(Fig. 4K-M). Finally, we also confirmed that OPA1 and MICU1 acts on angiogenesis 
through the same NFκB pathway. In line with the observed NFκB activation upon 
MICU1 ablation, when we simultaneously ablated P65 we corrected the migration, 
tubulogenesis and proliferation defects caused by MICU1 ablation (Fig. 4N-S). These 
results indicate that NFκB is required to mediate the anti-angiogenic effects of OPA1 
downregulation in all systems tested. 
 
Endothelial Opa1 ablation or pharmacological inhibition impairs tumor growth. 
Because tumor growth requires angiogenesis, we analyzed if endothelial Opa1 ablation 
had any effect on the size of several orthotopic tumor models. Growth of 
subcutaneously implanted mouse B16F10 melanoma as well as of mouse breast 
adenocarcinoma E0771 cells was curtailed in Opa1+/ΔEC mice (Fig. 5A-B; 
Supplementary Fig. 5A-B). When we visualized tumor vessels by immunostaining 
melanomas for the endothelial marker CD31, we noticed the expected enlargement of 
vessels in tumors growing in control mice. Diameter of tumor vessels and vascularized 
tumor area were conversely decreased when melanomas were grown in Opa1+/ΔEC 
mice, without affecting the total number of vessels (Fig. 5C-E; supplementary Fig. 
5C). The observed reduction in tumor growth could be also caused by increased anti-
tumor immunity in Opa1+/ΔEC mice, where the Tie2 driver used to ablate Opa1 from ECs 
can also drive Cre expression (and hence Opa1 deletion) in myeloid cells. However, 
tumoral recruitment of myeloid cells (CD11+, granulocytes, immature macrophages, 
macrophages and monocytes) was not affected in Opa1+/ΔEC mice (Supplementary 
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Fig. 5D). We conclusively excluded this possibility by verifying if also acute Opa1 EC 
ablation reduced tumor growth. To this end, Opa1iΔEC mice received a daily tamoxifen 
injection from P25-P30, resulting in a significant reduction in Opa1 mRNA in MPECs 
isolated from P60 Opa1iΔEC/+ and Opa1iΔEC mice (Supplementary Fig. 5E). This acute 
endothelial Opa1 ablation curtailed growth of B16F10 melanomas subcutaneously 
implanted in 2-month old mice (Fig. 5F-G) and reduced the diameter of blood vessels 
and the vascularized area of the tumor, without affecting the total number of vessels 
(Fig. 5H-J; Supplementary Fig.5F). We also determined whether this effect was 
specific for Opa1 ablation or caused by a general perturbation of mitochondrial fusion. 
To this end, Mfn1iΔEC mice received a daily tamoxifen injection from P25-P30, resulting 
in a significant reduction in Mfn1 mRNA in MPECs isolated from P60 Mfn1iΔEC mice 
(Supplementary Fig. 5G). However, growth of subcutaneously implanted B16F10 
melanomas was not affected in 2-month old Mfn1iΔEC mice (Supplementary Fig. 5H-I). 
Finally, we reasoned that tumor growth should be unaffected in P65,Opa1+/ΔEC mice 
where angiogenesis occurs normally. Indeed, the subcutaneously implanted 
melanomas grew as efficiently in control and in P65,Opa1+/ΔEC mice (Figure 5K-L). In 
addition, the reduction in blood vessels diameter and vascularized area observed in 
tumors grown in Opa1+/ΔEC and Opa1iΔEC mice was not recorded when the same type of 
tumors were implanted in P65,Opa1+/ΔEC mice (Supplementary Fig. 5J-M), further 
confirming that the effect of Opa1 ablation was a direct consequence of impaired 
angiogenesis. In conclusion, endothelial Opa1 ablation impairs tumor growth by a 
specific effect on tumor vascularization.  
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These data indicated the interesting possibility that acute Opa1 inhibition in endothelial 
cells can counteract tumor growth and metastasis. We therefore setup a proof of 
principle experiment to verify whether acute pharmacological Opa1 inhibition could 
curtail tumor growth. Melanomas were subcutaneously implanted and after 10 days we 
delivered by peritumoral injection 10 mg/kg/die of N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-
dihydro-1H-pyrazol-4-YL)-3-methyl-1-PH+ (MYLS22), the first in class safe and specific 
Opa1 inhibitor discovered in our laboratory (Pellattiero et al., 2019) (Supplementary 
Fig. 5N). Remarkably, tumor growth was curtailed to the same extent observed in 
Opa1+/ΔEC mice. Moreover, MYLS22 did not display any additive effect in Opa1+/ΔEC 
mice, further confirming its specific Opa1 targeting (Fig. 5M,N). In conclusion, genetic 
as well as pharmacological inhibition indicate that Opa1 is a targetable component of 
tumor angiogenesis.  
 
Endothelial Opa1 ablation prevents metastasis dissemination. 
Angiogenesis is not only involved in tumor growth, but also in tumor dissemination. 
Comforted by the finding that EC Opa1 is required for tumor growth, we decided to 
investigate if also metastatization required EC Opa1. To this end, first we used the well-
established experimental hematogenous metastasis assay in which B16F10 melanoma 
cells are injected in the tail vein (Elkin and Vlodavsky, 2001). Interestingly, the number 
of lung metastases was reduced by 75% in Opa1+/ΔEC mice (Fig. 6A,B). Because in this 
model tumor cells were directly injected into circulation, the first steps of metastatic 
dissemination (extracellular matrix degradation, tumor cells migration and intravasation) 
cannot be investigated. We therefore turned to the B16F10 footpad melanoma model, 
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metastases of which depend on both angiogenesis and lymphangiogenesis (Agrawal et 
al., 2014). Primary tumor growth was reduced in monoallelic and inducible endothelial 
Opa1 knockout mice (Fig. 6C-D, F-G). Because the foot lymphatic system drains 
through the popliteal lymph node (LN), primary B16F10 footpad tumors disseminate 
metastases to this popliteal LN. Interestingly, the frequency of sentinel LN metastases 
dropped from 48.5% in Opa1f/+ (n=33 LN analyzed) to 20.8% in Opa1+/ΔEC (n=24) and 
from 56.7% in Opa1f/f (n=30) to 28.6% in Opa1iΔEC (n=18). Even when metastases were 
identified in mice where EC Opa1 was deleted, their size was much smaller than that 
observed in their control littermates (Fig. 6E,H). In addition, cells were found in the 
lumen of blood vessels of primary melanomas implanted in the footpad of Opa1f/f but 
not Opa1iΔEC mice (Fig. 6I). Because EC Opa1 deletion did not affect the number (and 
type) of tumor infiltrating immune cells (Supplementary Fig. 5D), these are likely 
intravasating tumor cells, further supporting that inducible Opa1 ablation in EC curtails 
hematogenous metastasis. 
Tumor blood vessels are known to be enlarged and leaky because they are poorly 
covered by smooth muscle actin+ (SMA) pericytes, allowing intravasation of tumor cells 
to the circulation. We investigated whether the reduction of metastases dissemination in 
Opa1+/ΔEC mice could be explained by the normalization of tumor vessels diameter and 
pericytes coverage (Nagy et al., 2009; Ribeiro and Okamoto, 2015). In EC ablated 
Opa1 mice, tumor vessels were indeed smaller, less dense and more covered by 
pericytes (Fig.6J-N). While these results were reassuring, we could not exclude that the 
LN metastases reduction measured in the two models of EC Opa1 ablation was a mere 
consequence of the observed reduction in primary tumor size. We therefore turned to 
21 
 
ear implanted B16F10 tumors, which are drained by the lymphatic system (Bobek et al., 
2010). Primary tumor growth was unaffected in Opa1+/ΔEC mice (Fig. 6O,P), but the 
frequency of sentinel LN metastases was curtailed from 90.9% in Opa1f/+ (n=33) to 
28.6% in Opa1+/ΔEC mice (n=24). Moreover, size of the few metastases retrieved in 
Opa1+/ΔEC LN was greatly reduced (Fig. 6Q).  
Because tumor cells intravasation is orchestrated by pericyte-devoid lymphatic vessels 
(Cueni and Detmar, 2008), we reasoned that Opa1 deletion might have affected also 
lymphatic vessels that differentiate from veins (Simons and Eichmann, 2013). Indeed, 
the drainage of ear-injected Evan's Blue that requires lymphangiogenesis was impaired 
in Opa1+/ΔEC mice (Supplementary Fig. 6A,B). In addition, lymphatic vessels formation 
was affected by opa1 ablation in live transgenic stab1:YFP zebrafish embryos, 
expressing YFP in the lymphatic system (Supplementary Fig. 6C). To discriminate 
whether OPA1 ablation directly affected lymphatic function, or whether the lymphatic 
effects were secondary to venous defects, we turned to the lymphatic HMVEC-dly 
cellular model. OPA1 silencing blunted HMVEC-dly migration (Supplementary Fig. 
6D,E) and tubulogenesis (Supplementary Fig. 6F-H) without altering their proliferation 
(Supplementary Fig. 6I). Like in HUVECs, lymphatic OPA1 ablation causes a rewiring 
of lymphatic genes expression: the key regulators of lymphatic function PDPN, LYVE1, 
PROX1, FLT4 and NRP2 (Kong et al., 2017; Ou et al., 2015) were downregulated upon 
OPA1 ablation in HMVEC-dly (Supplementary Fig. 6J). In conclusion, EC Opa1 
ablation curtails tumor metastatization by normalizing tumor vessels and reducing tumor 
lymphangiogenesis.  
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Discussion  
The established notion that EC display a mostly glycolytic metabolism (Cruys et al., 
2016; Dobrina and Rossi, 1983; Krutzfeldt et al., 1990) reduced the interest on the role 
of mitochondria in angiogenesis, until the recent discovery that fatty acid and amino acid 
oxidation pathways are essential for angiogenic sprouting (Potente and Carmeliet, 
2017). However, whether mitochondria are involved in angiogenesis beyond their 
metabolic role is unknown. Our results indicate that the key fusion and cristae 
biogenesis protein Opa1 is recruited by the angiogenesis signaling cascade to provide 
the appropriate cues orchestrating vessel neoformation.  
A handful of studies suggest that under pathological conditions mitochondrial dynamics 
can modulate ECs functions. For example, hyperglycemia induces DRP1-dependent 
ROS production in ECs (Makino et al., 2010; Paltauf-Doburzynska et al., 2004; 
Shenouda et al., 2011). However, the key question of whether and to which extent 
mitochondrial dynamics participates in developmental angiogenesis remained 
unanswered. The involvement of mitochondria and mitochondrial dynamics in 
angiogenesis does not seem so surprising, given the energy demanding nature of this 
process. However, ECs mostly depend on glycolysis for ATP biosynthesis, raising the 
question of whether mitochondria participate at all in physiological angiogenesis. Our 
results not only identify a key mitochondrial protein as an essential component of 
angiogenesis, but they also extend the role of mitochondria in ECs beyond energy 
conversion. Mitochondrial elongation in response to angiogenic stimuli in vitro or in vivo 
in the developing mouse retinal and zebrafish intersomitic vessels is prominent and 
associated with an early increase in Opa1 levels. By capitalizing on several purposely 
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generated in vitro and in vivo models of constitutive and inducible Opa1 ablation in ECs, 
we unveil that Opa1 is essential for ECs migration, branching and filopodia number and 
length in tip cells. These processes require the integration of multiple signals to produce 
the appropriate space- and time-ordered cellular responses. It is noticeable that the role 
of OPA1 in angiogenesis does not depend on its established function in apoptosis and 
mitochondrial respiration (Cogliati et al., 2013; Frezza et al., 2006). Our data also 
exclude the possibility that mitochondrial fusion per se controls angiogenesis: the outer 
membrane MFNs are not regulated by angiogenic cues and dispensable for 
developmental and tumor angiogenesis, even if MFN1 or MFN2 ablation causes ECs 
apoptosis (Lugus et al., 2011). We therefore posit that the effect of OPA1 is specific and 
mediated by its ability to control transcription of essential angiogenes. Indeed, unbiased 
gene expression analysis reveals changes in the levels of 7.5% of the measured 
transcripts upon OPA1 deletion, among which a handful of essential angiogenic genes. 
Since our discovery that mitochondrial fusion directs cardiomyocyte differentiation and 
heart development by controlling transcription (Kasahara et al., 2013), mitochondrial 
morphology has been shown to control hematopoietic (Luchsinger et al., 2016) and 
mesenchymal stem cells (Forni et al., 2016) differentiation. It is interesting to note that 
fusion is embedded in these differentiation programs because of its ability to modulate 
transcription. Angiogenesis is no exception to this paradigm: Opa1 is placed at the 
crossroad between mitochondrial Ca2+ uptake and NFκB signaling to allow 
angiogenesis. When Opa1 is lacking, constitutive NFκB activation skews gene 
expression against angiogenesis, as demonstrated by genetic and pharmacological 
models of NFκB inhibition.  
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NFκB is a master regulator of EC function. While a handful of studies describe 
endothelial NFκB activation as proangiogenic (Andras et al., 2005; Kaplan et al., 2005; 
Soler et al., 1999), several reports illustrate the antiangiogenic effect of NFκB activation 
(Castellino and Ploplis, 2005; Mountain et al., 2007; Popov and Simionescu, 2006; 
Wilczynska et al., 2006; Xiao et al., 2005). Moreover, different types of angiogenesis 
inhibitors work through NFκB activation (Chen et al., 2006; Gingras et al., 2003; 
Tabruyn et al., 2003; Tadros et al., 2003), and transgenic mice expressing a dominant 
negative IκBα mutant under the control of Tie-2 promoter show an increase in tumor 
growth, further supporting an inhibitory role for NFκB in tumor angiogenesis (Kisseleva 
et al., 2006).  
Because OPA1 can regulate vascular biology, we explored its role in tumor growth and 
metastatization. Endothelial Opa1 is critical for tumor growth and for metastasis 
dissemination via lymphangiogenesis, providing a genetic proof of principle for targeted 
OPA1 inhibitors to treat angiogenesis-related diseases and cancer. This paradigm is 
further confirmed by the remarkable inhibition of tumor growth observed upon treatment 
with MYLS22, a specific, nontoxic small molecule Opa1 inhibitor identified in our 
laboratory (Pellattiero et al., 2019). The effects of MYLS22 on growth of implanted 
melanomas are fully dependent on endothelial Opa1, as confirmed by the lack of 
additive effects over Opa1 EC deletion. This proof of principle experiment indicate that 
Opa1 can be targeted in vivo by pharmacological means to counteract tumor growth. 
Indeed, OPA1 inhibition might be used to treat VEGFR-inhibitor-resistant tumors: by 
rewiring gene expression, OPA1 inhibition downregulates the angiogenic factors 
(FGFR, FGF, EGF, PDGF) used by tumors escaping from VEGF inhibitors. 
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Our work identifies a previously unappreciated role for Opa1 in coordinating EC function 
and highlights the potential of OPA1 inhibition as an anticancer strategy, by 
counteracting tumor angiogenesis and metastatization.  
 
Limitations of study.  
One obvious limitation of our study is the lack of additional pre-clinical models of 
hematogenous metastasis. The classic model of experimental hematogenous 
metastasis reported here (tail vein injection) does not recapitulate all the steps of 
metastasis. The additional models of metastasis employed in this study depend on both 
hematogenous and lymphatic metastatization. A model of orthotopic implantation 
followed by resection would for example further clarify how EC Opa1 is required for the 
initial steps of metastatization.  
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STAR Methods 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and 
will be fulfilled by the Lead Contact, Luca Scorrano (luca.scorrano@unipd.it).” 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Mouse models 
Animal housing and all the experimental procedures were authorized by the Italian 
Ministry of Health (383-2015-PR to LS). Mice were housed six per cage in a 
temperature (22-24°C) and humidity-controlled colony room, maintained on a 12-h 
light/dark cycle (07:00 to 19:00 light on), with standard food and water provided ad 
libitum and environmental enrichments. Endo-mito-EGFP mice were kindly provided by 
Dr. C. Vande Velde (Pickles et al., 2013). Cdh5(PAC)-CreERT2 mice were kindly 
provided by Dr. R.H. Adams (Wang et al., 2010), P65f/f by Dr. R.M. Schmid (Algul et al., 
2007) and Mfn1f/f by Dr. A. Zorzano (Boutant et al., 2017). Opa1+/ΔEC mice were 
generated by crossing Opa1f/f mice (Cogliati et al., 2013) with Tg(Tek-cre)2352Rwng 
(Tie2Cre) mice (Jackson’s Laboratory). Opa1iΔEC/iΔEC were generated by crossing 
Opa1f/f mice with Cdh5(PAC)-CreERT2 mice. Opa1f/f::Opa1tg mice were generated by 
crossing Opa1f/f with Opa1tg mice (Cogliati et al., 2013). The sequence of the primers 
used to genotype the mice are provided in Supplementary table S3. 
For the retinal neovascularization model, sex of the pups was not considered. For 
BAPTA intraocular injection, animals were first allocated to different groups based on 
their genotype and then randomized for injection with BAPTA or DMSO. We analyzed 
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first the vessel coverage of the retina, then the branching points and finally the tip cells 
content. For the retinal vascularization model, we analyzed 8-12 pups per group and 
age; in the case of P4 Opa1+/ΔEC and Opa1f/+, we analyzed 21-25 pups. 
For tumor experiments, we used 3-6 and 6-8-week-old females per group and we 
repeated each experiment twice. The allocation of mice in different group was based on 
their genotype. For in vivo matrigel experiment, we used 5-7 and 6-8-week-old males 
and we repeated the experiment twice. The allocation of mice in different group was 
based on their genotype. During all experiments, mice were monitored twice per day. 
Behavior, weight, furrow and tumor size were controlled every day. The total number of 
mice analyzed for each experiment is detailed in the figure legends.  
 
Zebrafish models 
Animal housing and all the experimental procedures were authorized by the Italian 
Ministry of Health (407/2015-PR to NT). Zebrafish (male and females) were housed 
twenty per thank (3.5 L) in a controlled water (temperature: 27-28°C, pH: 7.2-7.5, 
conductivity: 340-350 µs/cm, NO2=0 mg/L, NO3 50 mg/L, and maintained on a 12-h 
light/dark cycle (08:00 to 20:00 light on). Zebrafish were fed three times per day (2 times 
with dry food and once with artemia). Animals were maintained in tanks with 
environmental enrichment and mated in breeding tanks mimicking their natural 
reproductive habitat. Tg(fli1a:EGFP), Tg(kdrl:mCherry/kdrl-mls:GFP), Tg(stab1:YFP), 
Tg(kdrl:mCherry) zebrafish (Zebrafish International Resource Center, ZIRC, Oregon, 
USA) were grown and subjected to opa1 morpholino oligomers injections as previously 
described (Geudens et al., 2010). 
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Cell culture 
All cells were grown at 37°C in a 5% CO2 humid atmosphere. HUVECs (Lonza) were 
used from passages 3-9. Cells were seeded on 0.2% gelatin-coated dishes and 
maintained in culture in EGM-2 BulletKit medium (Lonza) supplemented with 5% fetal 
bovine serum (FBS). Experiments were performed in EGM2 medium supplemented 
when indicated with the VEGF (50ng/ml, Reliatech) or bFGF (10ng/ml, Promega).  
Primary neonatal human dermal lymphatic microvascular endothelial cells (HMVEC-
dLy) derived from a single donor (Lonza) were used from passages 1-7. Cells were 
seeded on 0.2% gelatin-coated dishes and maintained in EGM2-MV medium (Lonza).  
MPECs were used from passages 2 to 3. Cells were seeded on 0.2% gelatin-coated-
dishes and maintained in culture in EGM2 (Promocell).  
B16F10 mouse melanoma cells (ATCC-CRL-6475) and MDA-MB-231 human breast 
adenocarcinoma cells (ATCC-HTB26) were cultured in DMEM supplemented with 10% 
fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin.  
E0771 mouse breast adenocarcinoma cells were cultured in DMEM 4500 supplemented 
with 10% FBS, 20mM Hepes pH 7.4, 100 U/ml penicillin and 100 μg/ml streptomycin. 
 
Murine pulmonary microvascular endothelial cells isolation 
MPECs were isolated as described (Sobczak et al., 2010). Lungs were digested with 
collagenase/dispase solution (Roche Applied Science) at a final concentration of 2 
mg/ml for 45 min at 37°C. ECs were purified by using anti-PECAM-1 (CD31) (BD 
Pharmingen) antibody-conjugated Dynabeads for 15 min at room temperature. Finally, 
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beads were resuspended in EGM2 bullet kit (Lonza) medium and plated on gelatin 
coated dishes. When they reached 50% of confluence, a second purification step was 
performed using secondary anti-ICAM2 (BD Pharmingen)-conjugated Dynabeads 
(Invitrogen). MPECs were used between P2 and P4 for the different functional assays. 
 
METHOD DETAILS 
SiRNA transfection  
180,000 cells per well in a 6-well plate; 80,000 cells per well in a 48-well plate and 8,000 
cells per well in a 96-well plate were transfected with the following siRNAs: a non-
relevant human sequence (UNREL) (AM4635, Ambion20 nM), OPA1 (144409, 
Invitrogen 20 nM), OPA1 siRNA2 (36409, Invitrogen; used as a control in not shown 
data), P65 (40 nM), MICU1 siRNA (50nM), MFN1 (50 nM) and MFN2 (50 nM) using 
Dharmafect-4 (Dharmacon) according to manufacturer's instructions. All transfections 
experiments described in this paper were carried out with MFN1 and MFN2 siRNA1. 
Similar results were obtained with MFN1 and MFN2 siRNA 2 (data not shown). 
Functional assays on transfected HUVECs and evaluation of transfection efficiency 
were performed after 48 hours. HUVECs were trypsinized, stained with trypan blue and 
living cells were seeded for the different functional assays.  
 
Cell proliferation Assay  
HUVECs were transfected in a 96-well plate in 100µl EGM2 for 48 hours. The thymidine 
analogue 5-bromo-2-deoxyuridine (BrdU) was added and the culture was incubated for 
16 hours. BrdU incorporation was measured with the Cell Proliferation ELISA BrdU 
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chemiluminescence kit (Roche Applied Science) according to the manufacturer’s 
protocol. 
 
Scratch wound migration assay 
HUVECs were transfected in 48-well plate in 800 µL of EGM2 for 48 hours and were 
wounded with the head of a 200 µL tip. Migration of the cells into the wound was 
recorded 6 hours later.  
 
Capillary network formation on a Matrigel matrix 
5,000 HUVECs transfected as described above were plated in a 96-well plate pre-
coated with 35 µl Matrigel per well (BD Biosciences) 48 hours post-transfection. Cells 
were incubated in EGM-2 medium for 5h (Lonza). Brightfield images were taken using a 
Leica DM4000 epifluorescence microscope equipped with 4X, 1.3 NA objectives. 
Quantitative analysis of network structure was performed with ImageJ software by 
counting the number of intersections in the network and measuring the total length of 
the structures. 
 
NFκB binding activity 
The P65 DNA-binding activity of NFκB was quantified by ELISA (EZ Transcription 
Factor Kit NFκB P65, Pierce) according to the manufacturer's instructions on total 
protein extracts. Protein concentration was determined using the BCA protein assay 
reagent (Pierce). NFκB binding to the target oligonucleotide was detected by incubation 
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with primary antibody specific for the activated form of P65, visualized by anti-IgG 
horseradish peroxidase conjugates and developing solution. 
 
Calcium measurements 
Cells were incubated at 37°C in Hank’s balanced salt solution (HBSS, Sigma) 
containing 4% FBS and Fura2-AM (1 µM, Molecular Probes), pluronic acid 0.04% and 
minutes and resuspended in HBSS with 4%FBS (250,000 cells/experiment). Ratiometric 
Ca2+ measurements were performed at λem=340±5, 380±5 and λex=510±15 nm at 37°C 
in a LS50B fluorimeter (Perkin Elmer) equipped with fast filter and magnetic stirring. 
Background was calculated as the average of 10 seconds fluorescence intensity at the 
beginning of the experiment, i.e. HBSS+4%FBS. Basal level refers to average Ratio of 
10 timepoints (10s) upon addition of cells. The Ca2+-ATPase inhibitor thapsigargin 
refers to average Ratio of 10 s at the plateau. Rmax= average of 50 s upon reaching 
plateau. Rmin: average of 50 s at the end of experiment. Thapsigargin was used at a 
final concentration of 10 µM. 
 
Adenovirus infection 
Acute Opa1 ablation in Opa1f/f Opa1tg MPEC was obtained by infection with 
adenoviruses expressing Cre-GFP (ad-CRE; 300 pfu; Vector Biolabs). GFP (ad-EV)-
expressing adenoviruses were used as control at the same titer. 
 
Western blotting  
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Cells were lysed in lysis buffer and heated at 95°C for 10 min. Equal amounts of protein 
were resolved by 8% SDS PAGE and transferred to polyvinylidene fluoride membranes 
(PVDF) according to the manufacturer’s protocol. The blots were blocked for 1 hour at 
room temperature with 5% BSA (Sigma Aldrich) in Tris-buffered saline with 0.1% Tween 
20 (TBS-T) and probed overnight at 4°C with 1:1000 primary antibody. After three 
washes with TBS-T, the appropriate secondary antibody at a 1:5000 dilution was added 
for 1 hour at room temperature. The bands were visualized by enhanced 
chemiluminescence ECL kit (Pierce).  
 
Immunofluorescence  
HUVECs (3x105) were cultured in 35-mm dishes coated with gelatin (0.2%). After VEGF 
(50 ng/ml) incubation, cells were washed with PBS, fixed with 4% paraformaldehyde for 
15 min at room temperature, blocked and permeabilized with PBS-5%BSA-0.5% 
saponin solution, and incubated overnight in 1% PBS, 0.1% BSA-saponin (Sigma 
Aldrich) containing 1:100 primary antibody. After 3 washes with PBS cells were 
incubated with the same solution containing the corresponding secondary fluorescent 
antibodies Alexa Fluor 488 and 568 (Thermo Fisher Scientific) for 1 hour at room 
temperature. Samples were washed 3 times with PBS and nuclei were stained with 
DAPI. The samples were analyzed by confocal microscopy using the appropriate laser 
line of a LSM700 (Zeiss). 
For immunofluorescence on tissues, cryostat sections (5 µm thick) were fixed in 
acetone at -20°C and in 100% methanol at 4°C and then incubated with rat monoclonal 
anti-PECAM-1 for 1 hour at room temperature. Slides were washed and incubated with 
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Alexa 488 anti-rat for 1h at 4°C. After three washes, slides were covered with coverslips 
in mounting medium (Victor Laboratories) and analyzed using a Leica DMI4000 
microscope (equipped with 10X/0.25, 20X/0.35NA, 40X/0.6NA and 63X/1.25NA 
objectives). 
 
Tamoxifen treatment  
Tamoxifen injection in pups. To induce Tamoxifen-dependent ablation of Opa1 in the 
endothelium, pups were injected intraperitoneally every day from P1 until P3 with 50 µl 
Tamoxifen (1mg/ml) (Sigma-Aldrich). Retinal vascularization and evaluation of the Opa1 
deletion efficiency were performed from P5.  
Tamoxifen injection in adult mice. Mice of 15-20-day old were injected intraperitoneally 
for five consecutive days with 100 µl Tamoxifen (10 mg/ml). Tumors, matrigel injection 
and evaluation of Opa1 deletion efficiency were performed on 6-week old mice.  
 
Retinal murine neovascularization model  
To analyze postnatal neovascularization in the mouse retina, Opa1ΔEC/+, Opa1iΔEC, 
P65,Opa1ΔEC/+ and wild-type littermates were euthanized at the indicated postnatal day. 
Eyes were fixed in 4% paraformaldehyde (PFA) solution for 5 min, retinas were 
dissected and post-fixed in PFA 4% for 1 hour. After 5 washes with PBS, retinas were 
permeabilized in PBS with 1% BSA and 0.5% Triton overnight at 4°C. Retinas were 
then incubated with biotinylated isolectin B4 (Vector Laboratories) and mouse anti-Opa1 
(BD-Biosciences) for 4 hours at 4°C and washed overnight in PBS. Secondary 
streptavidin–Alexa 488 (Invitrogen), anti-mouse Alexa 488 (1:300) were added for 2 
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hours at 4°C. The secondary antibody was washed overnight, and retinas were flat-
mounted for the analysis conducted using Leica DMI4000 microscope (equipped with 
2.5X/0.07NA, 5X/0.12NA, 10X/0.25NA, 20X/0.35NA, 40X/0.6NA and 63X/1.25NA 
objectives). Images were analyzed using ImageJ. The retinal radius (from the optic 
nerve to the edge of the retina) and the vascular radius (from the optic nerve to the 
vascular front) of each petal of the retina were measured. The vascular coverage was 
calculated as the ratio between the vascular radius and the retinal radius of each petal 
of a single retina. Branching were quantified using ImageJ. Images of tip cell’s filopodia 
were taken by a confocal Zeiss LSM700 microscope (equipped with 10X/0.25, 
20X/0.50NA, 40X/1.3NA and 63X/1.4NA objectives) and images were analyzed using 
ImageJ. For BAPTA experiments, pups were intraocularly injected at P1 with 5 mM/eye 
of BAPTA-AM or DMSO and sacrificed at P5. 
 
Mouse tumor models 
Opa1+/ΔEC, Opa1iΔEC, Opa1+/iΔEC, P65,Opa1+/ΔEC, Mfn1iΔEC and the corresponding control 
mice were used throughout the study.  
Subcutaneous B16F10 melanoma model. Subconfluent B16F10 cells were trypsinized, 
washed and resuspended in PBS. B16F10 cell suspension (5x104 cells in 100µl PBS) 
was injected subcutaneously into the right flank of each mouse. Tumor growth of 
B16F10 cells was assessed by measuring the length and width of each tumor every day 
and calculating tumor volume by means of the formula: length x width2 x 0.5. Sixteen 
days after tumor cells injection, the mice were euthanized, and their tumors harvested.  
35 
 
In case of subcutaneous B16F10 melanoma treated with MYLS22, mice were treated 
from day 10 after tumoral cells injection every two days with 10mg/kg/die MYLS22 
resuspended in corn oil.  
Mammary E0771 adenocarcinoma model. Subconfluent E0771 cells were trypsinized, 
washed and resuspended in PBS. E0771 cell suspension (1.5x105 cells in 100 µl PBS) 
was injected in the the fourth mammary gland in the lower abdomen of each mouse. 
Tumor growth of E0771 cells was assessed by measuring the length and width of each 
tumor every day and calculating tumor volume as described above. Twenty-two days 
after tumor cells injection, mice were euthanized, and their tumors harvested.  
Footpad B16F10 melanoma model. 105 B16-F10 cells in 30 μl PBS were injected 
subcutaneously into the right hind footpad mice. Tumor growth was assessed by 
measuring the length and width of each tumor every day. Tumor volume was calculated 
as described above. Mice were euthanized, and tissues harvested 16 days after tumor 
inoculation.  
Ear B16F10 melanoma model.106 B16-F10 cells in 40μl PBS were injected between the 
skin and cartilage on the dorsal side of the ear. Tumor growth was assessed by 
measuring the length and width of each tumor every two days. Tumor volume was 
calculated as described above. Mice were euthanized, and tissues harvested 30 days 
after tumor inoculation. 
 
Matrigel plug assay 
Matrigel (500µl) supplemented with 250ng/ml FGF2, 400ng/ml VEGF and 0.0025 
Unit/ml heparin was implanted into mice under anesthesia in the right and left flank. 
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After 10 days, plugs were dissected from the mice and their weight were determined. 
Matrigels were ground in the presence of dispase solution (5mg/ml). The concentration 
of hemoglobin in the supernatant was determined directly by measuring the absorbance 
at 405 nm and compared with a standard curve of purified hemoglobin.  
 
Zebrafish experimental treatments 
For treatment with BAY 11-7082, embryos were placed in 12-well dishes (10-15 
embryos per well, with random allocation for embryos that were subjected to Opa1 
knockdown prior to control or inhibitor treatment). BAY 11-7082 (5 µm) or DMSO were 
added to the water at 12 hours post-fertilization (hpf). 
Live screening and quantification of vascular abnormalities in the trunk were performed 
on Tricaine-anesthetized embryos (Sigma-Aldrich) at 24 hpf (ISV sprouting), 72 hpf 
(lymphatic vessels in Tg(stab1:YFP)) and 5 days post fertilization (Tg(lyve1b:mCherry)). 
Embryos were anaesthetized and positioned on a coverslip in a drop of 1% low melting 
point agarose. Imaging for vascular defects were performed using a Nikon confocal 
microscope Eclipse 90i (equipped with water immersion 20X/0.50NA and 40X/0.80NA 
objectives). Imaging for mitochondrial morphology were performed using a spinning disk 
Andromeda confocal microscope (FEI) using a 60X/1.35NA oil immersion objective. 
 
Analysis of gene expression by qRT-PCR 
RNAs were extracted with the miRNeasy kit (Qiagen) according to the manufacturer’s 
protocol. cDNA synthesis was performed with 1 μg total RNA and the iScript cDNA 
Synthesis Kit (BioRad) according to the manufacturer’s instructions. Resulting cDNAs 
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(20 ng) were used for quantitative real-time PCR using the SYBR green method (Roche 
Applied Sciences). Thermal cycling was performed on an ABI Prism 7900 HT Sequence 
Detection System (Applied Biosystems). For all reactions, no template controls were 
run, and random RNA preparations were also subjected to sham reverse transcription to 
check for the absence of genomic DNA amplification. Quantitative real-time PCR was 
performed with SYBR green method (Bioline and ThermoFisher Scientific). Thermal 
cycling was performed on an Applied Biosystem 7900 HT detection system and a 
Stratagene MX3005P multiplex QPCR system (Applied Biosystems and Stratagene).  
The relative transcript level of each gene was normalized to the housekeeping genes 
cyclophilin-A (PPIA), beta-2 microglobulin (B2M) and/or GAPDH. Primers were 
designed using Primer Express software and selected to span exon-exon junctions to 
avoid detection of genomic DNA (primer sequences are provided in supplementary 
tables S1 and S2). Quantification of mRNA levels was calculated with the 2-ΔCt method. 
 
RNA sequencing experiment 
RNA sequencing was performed by the GIGA Genomics Facility (Liège, Belgium). After 
30h of transfection with 30 nM of Unrel or OPA1 siRNA, total RNA was isolated from 
HUVECs using RNeasy Mini Kit (Qiagen). Extracted RNA yields were determined using 
a NanoDrop® ND-1000 spectrophotometer (Thermo Fisher Scientific). The purity and 
quality of extracted RNAs were evaluated using the Experion RNA StdSens Analysis kit 
(Bio-Rad). High quality RNAs with RNA Quality Indicator (RQI) score greater than 8 
were used for RNA sequencing experiments. Gene expression profiling was performed 
using An Illumina NextSeq500. For each sample, 250ng of total RNA were labeled 
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using an Illumina Total Prep RNA Amplification kit (Ambion) according to the 
manufacturer’s instructions. The raw sequence reads were aligned by STAR (reference 
genome HOMO SAPIENS UCSChg19). The differential genes expression and their 
false discovery rate (FDR) corrected p values were calculated using DESeq2 (v. 1.6.3) 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Data representation and Statistical analysis  
Data are displayed as dot plots of at least three independent experiments. Plots include 
each datapoint, mean and SEM. In case of tumor growth curve, average±SEM is 
represented. 
Statistical significance was calculated by a one-way ANOVA with Tukey’s post-test. All 
P values and n are reported in the figure legends. Results are considered significant 
when p<0.05.  
 
DATA AND SOFTWARE AVAILABILITY 
Accession Number 
RNA sequencing data have been deposited in GEO (accession #GSE122042). 
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit anti-IκBα (C-21) Santa Cruz Biotechnology SC-371 
Mouse anti-Opa1 BD-Biosciences 612607 
rabbit anti-GRP75 Santa Cruz Biotechnology sc-13967 
Mouse anti-MICU1 Sigma Aldrich #ACC-322 
rabbit anti-P65 Cell Signalling Technology 8242 
Rabbit anti-Tom20 (FL-145) Santa Cruz Biotechnology sc-11415 
SDHA antibody Abcam ab14715 
Rabbit anti-STAT3 Cell Signalling 4904 
Rabbit anti-phospho-STAT3 (Tyr 705) Cell Signalling 9131 
Isolectin b4 Vector Laboratories  B1205 
Rat anti mouse CD31  BD Pharmingen  550274  
Anti mitofusin 1 NeuroMabs  75162  
Anti mitofusin 2 ABM  Y401293  
Anti-Actin-α-smooth muscle-CY3 Sigma Aldrich C6198 
Goat anti-esm1 R&D Systems  AF1999  
Rat Anti-Mouse CD102 BD Pharmigen  553326  
Goat anti-VEGFR2 R&D Systems  AF357 
Rabbit anti GRP75 Santa Cruz  
Mouse anti-VE-Cadherin BD-Biosciences 610251 
Rabbit anti-ERK1/2-phospho, p44/42 MAPK 
Phospho  
Cell Signaling Technology  9101 
Rabbit anti-ERK1/2, p44/42 MAPK Cell Signaling Technology  4695  
Rabbit anti-AKT pan (11EZ)  
 
Cell Signaling Technology  4685 
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Rabbit anti-AKT Phospho (Thr308) (C31E5E)  Cell Signaling Technology 2965 
Rabbit anti-Phospho-Akt (Ser473) Antibody Cell Signaling Technology 9271 
Rabbit anti-CD11 Cell Signaling Technology 45581 
Alexa Fluor 488 donkey anti goat IgG Life Technologies  A11055  
Alexa Fluor 488 goat anti mouse IgG Life Technologies  A11029 
Alexa Fluor 488 goat anti rabbit IgG Life Technologies  A11070 
Alexa Fluor 488 Chicken anti-Rat IgG Life Technologies  A21470 
Alexa Fluor 594 Donkey Anti-Goat IgG Abcam ab150136 
Alexa Fluor 594 Donkey anti-Rabbit IgG Thermo fisher A10042 
Alexa Fluor 568 Goat anti-Rat IgG Thermo fisher A-11077  
Alexa Fluor 568 Goat anti-Mouse IgG Thermo fisher A-11019 
Streptavidin Alexa Fluor 555 conjugate Life Technologies  S21381 
Streptavidin Alexa Fluor 488 conjugate Life Technologies  S11223 
Amersham ECL Mouse IgG, HRP-linked (sheep) GE Healthcare NA931 
Amersham ECL Rabbit IgG, HRP-linked (donkey) GE Healthcare NA934 
Bacterial and Virus Strains  
Biological Samples   
Chemicals, Peptides, and Recombinant Proteins 
VEGF165 Vinci-Biochem Srl Rel 300-076 
bFGF  Promega  G5071  
BAY 11-7082 Calbiochem A00308 
BAPTA, AM  Thermo Fisher Scientific  B6769  
LLL12 Sigma Aldrich 573131 
AG490 Calbiochem 133550-30-8 
PD98059 Calbiochem 167869-21-8 
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Sigma Aldrich Sigma Aldrich W1628 
Evans Blue  Sigma-Aldrich  E2129 
Fura-2, AM  Life Technologies  F1221  
Tricaine Sigma-Aldrich  A-5040 
Rhodamine B Sigma Aldrich  83689 
Rotenone Sigma-Aldrich R8875-1G  
FCCP Sigma-Aldrich C2920 
Antimycin A Sigma-Aldrich A8674 
Oligomycin Sigma-Aldrich O4876 
TMRM Invitrogen T668 
MYLS22 Enamine EN300-333633 
Thapsigargin  Sigma-Aldrich T903  
Heparin, endotoxin free  Sigma-Aldrich 2106 
Collagenase, Dispase Roche 10269638001  
Dispase II Sigma-Aldrich D4693 
Trypan Blue Solution, 0.4% Thermo Fisher Scientific 15250061 
Tamoxifen Sigma-Aldrich  T5648-5G  
Matrigel matrix 3D VWR 7341100 
Haemoglobin human Sigma-Aldrich  H7379 
Dharmafect 4  Dharmacon T-2004-03 
Critical Commercial Assays 
SensiMix Sybr NO-ROX Kit Bioline QT650-05 
BrdU Chemiluminescence Kit Roche 11647229001 
EZ transcription Factor Kit NFκB P65 Pierce 89859 
RNeasy Mini Kit Qiagen 74104 
Experion RNA StdSens Analysis kit Bio-Rad 7007103 
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Pierce protein BCA assay Thermo Fisher 23225 
Annexin V-FITC Apoptosis Detection Kit  eBioscience  BMS500FI/300  
Deposited Data 
RNA sequencing data GEO GSE122042 
Experimental Models: Cell Lines 
HUVEC Pooled, in EGMTM-2 Lonza C2519A 
HMVEC-dLy Ad, Adult Lonza CC-2810 
Human Breast Adenocarcinoma MDA MB231 ATCC ATCC-HTB26 
Murine melanoma B16F10 ATCC ATCC-CRL-6475 
Mouse breast Adenocarcinoma E0771 Tebu-Bio 940001-A 
Experimental Models: Organisms/Strains 
Endo-mito-EGFP mice Pickles et al., 2013 N/A 
Cdh5(PAC)-CreERT2 mice Wang et al., 2010 N/A 
P65f/f mice Algul et al., 2007  
Tg(Tek-cre)2352Rwng (Tie2Cre) mice Jackson's laboratory 008537 
Opa1f/f mice Cogliati et al., 2013 N/A 
Opa1ΔEC/+ mice This paper N/A 
Opa1iΔEC mice This paper N/A 
Opa1tg mice Varanita et al., 2015 N/A 
Opa1f/f Opa1tg mice This paper N/A 
Mfn1iΔEC mice This paper. N/A 
Tg(kdrl:GFP) zebrafish Liu et al., 2007 N/A 
Tg(kdrl:mCherry) zebrafish Wang et al., 2010 N/A 
Tg(kdrl:mCherry/kdrl-mls:GFP) zebrafish D. Stainier, MPI, Germany N/A 
Tg(stab:YFP) zebrafish Hogan et al., 2009 N/A 
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Tg(fli1a:GFP) zebrafish Lawson et al., 2002 N/A 
Oligonucleotides  
siRNA   
OPA1 siRNA 1 Invitrogen 144409 
OPA1 siRNA 2 Invitrogen 36409 
Unrel Ambion AM4635 
P65 siRNA 5'-GCC CUA UCC CUU UAC GUC 
AdTdT-3' 
Halkein et al., 2013 N/A 
SCR siRNA 5'-UCG ACC UCA CUU CCC AUU G-
3'.  
Halkein et al., 2013 N/A 
MFN1 siRNA 1 5'-GGC GAU UAC UGC AAU 
CUU U-3', 
De Brito et al., 2008 N/A 
MFN1 siRNA2 5'-CCA GAU GAA CCU UUU AAC 
A-3' 
De Brito et al., 2008 N/A 
MFN2 siRNA1 5'-GGA GAG GGC CUU CAA GCG 
C-3' 
De Brito et al., 2008 N/A 
MFN2 siRNA2 5'-GAG ACA CAU GGC UGA GGU 
G-3' 
De Brito et al., 2008 N/A 
MICU1 siRNA 5'-
GACUUCGCUUUACCCAAACAG-3' 
Patron et al., 2014 N/A 
Morpholino oligos   
opa1 translation blocking morpholino 
GATGAGTTTAGGATCTCTTTGCAGT 
Rahn et al., 2013 N/A 
unrel morpholino 
GATCACTTTACGATCTGTTTCCAGT 
Rahn et al., 2013 N/A 
Recombinant DNA 
Software and Algorithms 
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Origin   
Corel Draw   
Image J   
RNA Express Version 1.1.0 Illumina Base Space   
Deseq2 version 1.6.3   
STAR   
Other 
EGM2 (Endothelial growth medium) Promocell C-22011 
Endothelial cell growth factor supplements Promocell C-30120 
Gelatin from bovine skin SIgma aldrich G9391 
DMEM Gibco 31885049  
Penicillin-streptomycin (5000U/ml) Invitrogen 15070-063 
cOmplete™, Mini, EDTA-free Protease Inhibitor 
Cocktail  
Roche 4693159001 
PhosStop Phosphatase Inhibitor Cocktail Tablets Roche 04906845001 
Amersham Hybond 0.45um PVDF  Thermo Fisher Scientific  15407374  
ExpressPlus PAGE Gel, 10x8, 8% 12 wells  GenScript  M00812 
ExpressPlus PAGE Gel, 10x8, 4-12% 10 wells  GenScript  M41210 
Trypsin-EDTA (0.25%) Thermo Fisher 25200056 
Bovine Serum Albumin Sigma Aldrich A8806 
Zoletil 50 VIRBAC 7978320 6/2016 
ROMPUN BAYER HEALTHCARE 4222764 3/1980 
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Figure legends 
Figure 1: Mitochondria elongate during angiogenesis.  
(A) Representative confocal image of intersomitic vessels (ISVs) of zebrafish 
Tg(kdrl:mCherry/kdrl-mls:GFP) at 24 hpf showing blood vessels (red) and endothelial 
mitochondria (green). Scale bar: 100 µm.  
(B) Representative confocal GFP imaging of living flat-mounted retinas from adult Endo-
MitoEGFP mouse showing mitochondria in blood vessels. Scale bar: 150 µm.  
(C-D) Representative GFP imaging of living stalk and tip endothelial cells in flat-
mounted retinas extracted from Endo-MitoEGFP mouse at P4. Scale bar: 150 µm.  
(E) Box plot of mitochondrial length in experiments as in C,D. Each dot represents 1 
mitochondrion (n=50, 3 independent mice). *: p=5x10-15 adult vs. stalk cells; p=2x10-11 
tips vs. stalk cells.  
(F) Representative confocal images of mitochondrial morphology in HUVEC treated for 
1h as indicated and stained for TOM20. Scale bar: 30 µm.  
(G) Box plot of mitochondrial length in experiments as in F. Each dot represents 1 
mitochondrion, n=3 independent experiments. *: p=4x10-14 untreated vs. VEGF. 
(H) Heat map of transcriptional changes measured by RNA sequencing during VEGF 
treatment (1,4 and 12h) of HUVEC. Data are resorted from http://angiogenes.uni-
frankfurt.de and elaborated as detailed in the text.  
(I) Average±SEM of 3 independent experiments of OPA1, MFN1 and MFN2 mRNA 
levels in HUVEC treated with VEGF (50 ng/ml) as indicated. *: p<0.05.  
(J) Equal amounts of protein from HUVEC treated where indicated with VEGF (50 
ng/ml) were separated by SDS-PAGE and immunoblotted with the indicated antibodies.  
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(K) Schematic representation of late retinal vascular development. In this model, from 
P7 onwards the superficial vascular plexus (L1) and blood vessels sprout to form the 
deeper layer (L3). 
(L) Representative confocal image vascular layer 1, stained for OPA1 (green) and 
isolectin b4 (red) showing blood vessels from WT mice at P6. F represents the forefront 
where tip cells are located. Scale bar: 100 µm.  
(M) Representative confocal images of vascular layer 1 (L1, quiescent ECs) and 3 (L3, 
angiogenic ECs) of retina extracted from WT mice at P11, fixed and stained for OPA1 
(green) and isolectin b4 (red) to mark blood vessels. Scale bar: 150 µm. 
 
Figure 2: Opa1 is required for angiogenesis in vitro and in vivo.  
(A) Representative isolectin b4 immunofluorescence (magnification 2.5x) of flat-
mounted retinas from 5-day-old pups of the indicated genotype. Scale bar: 50 µm.  
(B) Quantification of radial expansion. Experiments were performed as in (B). *: 
p=0.005, n=5 mice.  
(C) Representative brightfield images acquired at the indicated time points of MPEC 
from 4-day old pups of indicated genotype in a scratch-wound assay. Scale bar: 250 
µm.  
(D) Quantification of cellular migration after 6h in experiments as in (C). n=6 
independent experiments, n>4 mice per genotype. *: p=0.008.  
(E) Quantification of proliferation of MPEC extracted from 4-day old pups of indicated 
genotype determined by BrdU incorporation. n=4 independent experiments, n>4 mice 
per group. *: p=6x10-5.  
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(F) Representative isolectin b4 immunofluorescence (magnification 2.5x) of flat-
mounted retinas from 4-day-old pups of the indicated genotype. a (red) indicates the 
radius of vascular front and b (yellow) the radius of retina. Scale bar: 50 µm.  
(G) Quantification of radial expansion calculated as the ratio between the radius of 
vascular front (a) and the radius of retina (b). Experiments were as in (F). *: p=5x10-12; 
n=21 Opa1f/+ and 25 Opa1+/ΔEC mice. 
(H) Representative isolectin-b4 immunofluorescence (magnification 5x) of flat-mounted 
retinas showing blood vessels and branching points from 4-day-old pups of the 
indicated genotype. Scale bar: 100 µm.  
(I) Quantification of branching points/mm2 of retina. Experiments were performed as in 
(H). *: p=3x10-6; n=11 Opa1f/+ and 10 Opa1+/ΔEC mice.  
(J) Representative isolectin b4 immunofluorescence (magnification 40x) of flat-mounted 
retinas from 4-day-old pups of the indicated genotype. Red arrows mark tips cells. Scale 
bar: 20 µm.  
(K) Quantification of tip cells number. Experiments were performed as in (J). *: p=5x10-
5; n=10 Opa1f/+ and 8 Opa1+/ΔEC mice.  
(L) Representative isolectin b4 immunofluorescence (magnification 2.5x) of flat-mounted 
retinas from 6-day-old pups of the indicated genotype injected with tamoxifen at P1-P3. 
a (red) indicates the radius of vascular front and b (yellow) the radius of retina. Scale 
bar: 50 µm. 
(M) Quantification of radial expansion calculated as the ratio between the radius of 
vascular front (a) and the radius of retina (b) in experiments as in (L). *: p= 4x10-5; n=10 
Opa1f/f and 11 Opa1iΔEC mice.  
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(N) Representative isolectin b4 immunofluorescence (magnification 5x) of flat-mounted 
retinas showing blood vessels and branching points in 6-day-old pups of the indicated 
genotype. Scale bar: 100 µm.  
(O) Quantification of branching points/mm2 of retina. Experiments were performed as in 
(N) in 6-day-old pups of the indicated genotype. *: p=8x10-6; n=11 Opa1f/f and 11 
Opa1iΔEC mice.  
(P) Representative isolectin b4 immunofluorescence (magnification 40x) of flat-mounted 
retinas showing blood vessels and tips cells (red arrows) from 6-day-old pups of the 
indicated genotype. Scale bar: 20 µm.  
(Q) Quantification of number of tip cells. Experiments were performed as in (P) from 6-
day-old pups of the indicated genotype. *: p=2x10-7; n=10 mice/genotype. 
(R) Equal amounts of protein from zebrafish injected for 48h with opa1 morpholino as 
indicated were separated by SDS-PAGE and immunoblotted with the indicated 
antibodies. 
(S) Representative confocal images of endothelial mitochondria in intersomitic vessels 
of Tg(kdrl:mls:GFP) zebrafish 24h post injection with the indicated morpholino. Scale 
bar: 100µm.  
(T) Quantification of mitochondria length in intersomitic blood vessel of zebrafish 
injected with the indicated morpholinos. Each dot represents 1 mitochondrion. n=40 
mitochondria from 3 independent experiments. *: P=2x10-9 unrel vs. opa1.  
(U) Representative confocal images of sprouting of intersomitic vessels (ISV) of 
Tg(fli1a:GFP) zebrafish 30h after injection with the indicated morpholino. Scale bar: 100 
µm.  
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(V) Quantification of number of ISVs sprouts (black) and filopodia length (blue) in 
experiments as in (U). *: p=4x10-5 (number); n=12 unrel and 14 opa1 morphants; *: 
p=8x10-5 (length); n=15 unrel and 16 opa1 morphants.  
(W) Representative photographs of Matrigel plugs implanted 8 days in 6-week-old mice 
of the indicated genotype. Scale bar: 0.3 cm.  
(X) Quantification of hemoglobin content in Matrigel plug. Experiments were performed 
as in (W). *: p= 8x10-6; n=14 Opa1f/+ and 10 Opa1+/ΔEC mice. 
 
Figure 3: Opa1 orchestrates NFκB signaling and angiogenic gene expression. 
(A) 2Δct of OPA1 mRNA levels determined by RT-PCR in HUVEC treated as indicated. *: 
p<0.05; n=3 independent experiments.  
(B) Opa1f/f::Opa1tg MPEC were infected with the indicated adenoviruses and after 48 
hrs treated where indicated for 10 minutes with VEGF (50ng/mL) and lysed. Equal 
amounts of protein (40 µg) were separated by SDS-PAGE and immunoblotted with the 
indicated antibodies. 
(C) Opa1f/f::Opa1tg MPEC were infected with the indicated adenoviruses and after 48h 
treated where indicated with VEGF for 6h. Cellular migration was quantified at 6h in a 
scratch wound assay. *: p<0.05; n=6 independent experiments. 
(D) Opa1f/f::Opa1tg MPEC were infected with the indicated adenoviruses and after 48h 
treated where indicated with VEGF for 24h. Cellular proliferation was quantified by 
measuring BrdU incorporation after 24h. *: p<0.05; n= 3 independent experiments. 
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(E) Total cellular ATP levels were measured in HUVEC transfected for 48h with the 
indicated siRNA as indicated (n=20 independent experiments) and in MPEC isolated 
from P4 pups of the indicated genotype (n=12 mice/condition).  
(F) Volcano plot of differentially expressed genes in HUVEC transfected for 32h with 
siRNA against OPA1 or a non-relevant sequence (UNREL). Red and green dots 
correspond to genes down-regulated and upregulated in Opa1-ablated HUVECs. n=3 
independent experiments. 
(G) Average±SEM of expression levels of the indicated genes in HUVEC transfected for 
32h with OPA1 siRNA determined by RT-PCR in 4 independent experiments. *: p<0.05.  
(H) Bubble plot of pathway perturbation vs. over-representation from the RNAseq 
experiments. The graph plots the -log10 of the p-values of the two types of evidence 
computed by iPathwayGuide: over-representation (pORA) and total pathway 
accumulation (pAcc). Each pathway is represented by a single bubble, whose size is 
proportional to pathway representation. Red: significantly altered pathways; yellow: 
significantly altered pathways involving NFκB proteins regulators.  
(I) Fold changes of genes involved in the NFκB pathway in HUVEC transfected with 
OPA1 siRNA compared to UNREL siRNA. Experiment is performed as in (G). n=3 
independent experiments.  
(J) HUVEC were transfected with the indicated siRNA and after 48h the P65 DNA-
binding ability was determined by a specific ELISA. *: p=0.02; n=6 independent 
experiments.  
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(K) HUVEC were transfected with the indicated siRNA and after 48h treated where 
indicated with VEGF (50ng/ml). The P65 DNA-binding ability was determined by a 
specific ELISA. *: p<0.05; n=3 independent experiments. 
(L) Equal amounts of protein extracted from HUVEC transfected 48h with siRNA as 
indicated were separated by SDS-PAGE and immunoblotted with the indicated 
antibodies. 
(M) Opa1f/f MEFs were infected with the indicated adenovirus and after 48hrs 
mitochondria were isolated and protein complexes were separated BN-PAGE, 
transferred onto a PVDF membrane, and probed with the indicated antibodies. The 
boxed area highlights the reduced MICU1-MCU-Opa1 containing complex.  
(N) Quantification of Fura-2 Ratio (proportional to cytosolic Ca2+ levels) in HUVEC 
transfected for 48h with the indicated siRNAs. *: p=0.001 UNREL vs. OPA1; p=0.02 
UNREL vs. MICU1; p=0.04 UNREL vs. OPA1, MICU1; n=4 independent experiments. 
NS: not significant.  
(O) Equal amounts of protein extracted from HUVEC transfected 48h with the indicated 
siRNA and treated with BAPTA (1 mM) for 8h as indicated were separated by SDS-
PAGE and immunoblotted with the indicated antibodies.  
(P) HUVEC were transfected with the indicated siRNA and after 48h treated where 
indicated with BAPTA (1mM) for 8h. The P65 DNA-binding ability was determined by a 
specific ELISA. *: p=0.0003 UNREL vs. OPA1; #: p=0.002 OPA1,DMSO vs. 
OPA1,BAPTA; n=5 independent experiments 
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(Q) Representative brightfield images at the indicated time points of a scratch-wound 
assay using HUVEC transfected with the indicated siRNA for 48h and treated as 
indicated. Scale bar: 100µm.  
(R) Quantification of cellular migration at 6h in experiments as in Q. *: p<0.05; n=6 
independent experiments.  
(S) Representative isolectin b4 immunofluorescence (magnification 2.5x) of flat-
mounted retinas from 5-day-old pups of the indicated genotype treated where indicated 
with BAPTA-AM (5mM) delivered by intravitreal injection at P1. Scale bar: 50µm.  
(T, U) Quantification of radial expansion (T) and branching points (U) in experiments as 
in S. *: p=3x10-5 (T) and 2x10-5 (U) Opa1f/+-vehicle vs Opa1 -vehicle; #: p=1x10-6 (T) 
and 0.003 (U) Opa1+/ΔEC-vehicle vs. Opa1+/ΔEC-BAPTA. n=10 Opa1f/+-vehicle, 8 
Opa1+/ΔEC-vehicle and Opa1f/+-BAPTA, 7 Opa1+/ΔEC-BAPTA mice.  
 
 
(A) Representative brightfield images acquired at the indicated time points of scratch 
wound assays of HUVEC transfected for 48h with the indicated siRNA. Scale bar: 100 
µm.  
(B) Quantification of cellular migration after 6h in experiments as in (C). *: p=6x10-5 
UNREL,SCR vs SCR,OPA1; #: p=5x10-5 SCR,OPA1 vs. P65,OPA1; n=6 independent 
experiments. 
(C) Representative brightfield images of endothelial tubular network in HUVEC 
transfected with the indicated siRNA and seeded on Matrigel for 6h. Scale bar: 200 µm.  
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(D) Quantification of branching points in experiments as in C. *: p=0.001 UNREL,SCR 
vs SCR,OPA1; #: p=0.0021 SCR,OPA1 vs. P65,OPA1; n=7 independent experiments.  
(E) Quantification of tube length o in experiments as in C. *: p=7x10-6 UNREL,SCR vs 
SCR,OPA1; #: p=1x10-10 SCR,OPA1 vs. P65,OPA1; n=6 independent experiments.  
(F) Representative isolectin b4 immunofluorescence (magnification 2.5x) of flat-
mounted retinas showing blood vessels from 6-day-old pups of the indicated genotype 
injected with tamoxifen at P1-P3. a (red) indicates the radius of vascular front and b 
(yellow) the radius of retina. Scale bar: 50 µm.  
(G) Quantification of radial expansion calculated as the ratio between the radius of 
vascular front (a) and the radius of retina (b) in experiments as in (F). *: p=1x10-6 
Opa1f/+ vs. Opa1+/ΔEC; #: p=0.01 Opa1+/ΔEC vs. P65,Opa1+/ΔEC; n=7 P65f/+, 9 P65+/ΔEC, 8 
P65,Opa1f/+, 18 P65,Opa1+/ΔEC, 13 Opa1f/+ and 7 Opa1+/ΔEC mice.  
(H) Quantification of branching points/mm2 of retina. Experiments were performed as in 
F in 5-day-old pups of the indicated genotype. *: p=6x10-5 Opa1f/+ vs. Opa1+/ΔEC, #: p 
=2x10-7 Opa1+/ΔEC vs. P65,Opa1+/ΔEC; n=5 P65f/+, P65+/ΔEC and P65,Opa1f/+, 9 
P65,Opa1+/ΔEC, 8 Opa1f/+ and 6 Opa1+/ΔEC mice.  
(I) Quantification of total venous branching points/mm of vein. Experiments were 
performed as in F in 5-day-old pups of the indicated genotype. *: p=3x10-5 Opa1f/+ vs. 
Opa1+/ΔEC, #: p=2x10-5 Opa1+/ΔEC vs. P65,Opa1+/ΔEC; n=5 P65f/+, 7 P65+/ΔEC, 8 
P65,Opa1f/+, 12 P65,Opa1+/ΔEC, 10 Opa1f/+ and 11 Opa1+/ΔEC mice.  
(J) Quantification of distal venous branching points. Experiments were performed as in 
F from 5-day-old pups of the indicated genotype. *: p=2x10-5 Opa1f/+ vs. Opa1+/ΔEC; #: 
70 
 
p=5x10-6 Opa1+/ΔEC vs. P65,Opa1+/ΔEC; n=7 P65f/+, 11 P65+/ΔEC, 10 P65,Opa1f/+, 14 
P65,Opa1+/ΔEC, 12 Opa1f/+ and Opa1+/ΔEC mice.  
(K) Representative confocal images of sprouting of intersomitic vessels (ISV) of 
zebrafish Tg(fli1a:GFP) showing blood vessels at 30h post morpholino injection and 
treated as indicated. Scale bar: 100 µm.  
(L) Quantification of number of ISV filopodia. Experiments were performed as in K. *: 
p=2x10-6 unrel-DMSO vs. opa1-DMSO; #: p=3x10-7 opa1-DMSO vs. opa1-BAY11-7082; 
n=11 unrel, 18 opa1, 9 unrel-BAY11-7082 and 14 opa1-BAY11-7082 zebrafishes.  
(M) Quantification of filopodia length of ISV. Experiments were performed as in K. *: 
p=1x10-4 unrel-DMSO vs. Opa1-DMSO; #: p=2x10-5 opa1-DMSO vs. opa1-BAY11-
7082; n=6 unrel, n=10 opa1, n=5 unrel-BAY11-7082 and n=7 opa1-BAY11-7082 
zebrafishes.  
(N) Representative brightfield images acquired at the indicated time points of scratch 
wound assays of HUVEC transfected for 48h with the indicated siRNA. Scale bar: 100 
µm.  
(O) Quantification of cellular migration after 6h in experiments as in (N). *: p<0.05, n=8 
independent experiments.  
(P) Representative brightfield images of endothelial tubular network in HUVEC 
transfected with the indicated siRNA and seeded on Matrigel for 6h. Scale bar: 250 µm.  
(Q) Quantification of branching points in experiments as in P. *: p<0.05, n=5 
independent experiments.  
(R) Quantification of tube length in experiments as in P. *: p<0.05, n=5 independent 
experiments.  
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(S) Quantification of cellular proliferation as determined by BrdU incorporation after 24h 
in HUVEC transfected for 48h with the indicated siRNA. *: p<0.05; n=6 independent 
experiments.  
 
Figure 5: EC Opa1 deletion or inhibition curtails tumor growth  
(A) Photographs of representative melanomas removed after 16 days from 
subcutaneous implants of 5x104 B16F10 cells in 6-week-old mice of the indicated 
genotype. Scale bar: 0.5 cm.  
(B) Growth curves of subcutaneously implanted 5x104 B16F10 melanomas at day 0 in 
6-week-old mice of the indicated genotype. n=7 Opa1f/+ and 9 Opa1+/ΔEC mice. *: 
p<0.05.  
(C) Representative CD31 immunofluorescence (red) showing blood vessels in B16F10 
melanomas in experiments as in A. Scale bar: 100 µm.  
(D, E) Quantification of tumor blood vessels diameter (D) and surface per field (E) in 
experiments as in C.*: p=0.005 (D) and 0.009 (E). n=7 Opa1f/+ and 9 Opa1+/ΔEC mice.  
(F) Representative photographs of melanomas removed after 16 days from the 
subcutaneous implants of 5x104 B16F10 cells in 6-week-old mice of the indicated 
genotype. Scale bar: 0.5 cm. 
(G) Growth curves of 5x104 B16F10 melanoma cells subcutaneously implanted at day 0 
in 6-week-old mice of the indicated genotype. n=7 Opa1f/+ and Opa1f/f, 9 Opa1+/iΔEC and 
Opa1iΔEC mice. *: p<0.05.  
(H) Representative CD31 immunofluorescence (red) showing blood vessels in B16F10 
melanomas in experiments as in G. Scale bar: 100 µm.  
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(I,J) Quantification of tumor blood vessels diameter (I) and surface per field (J) in 
experiments as in C.*: p<0.05. n=8 Opa1f/f and 9 Opa1iΔEC mice.  
(K) Representative photographs of melanomas removed after 16 days from 
subcutaneous implants of 5x104 B16F10 cells in 6-week-old mice of the indicated 
genotype. Scale bar: 0.5 cm. 
(L) Growth curves of 5x104 B16F10 melanoma cells subcutaneously implanted at day 0 
in 6-week-old mice of the indicated genotype. *: p<0.05 n=11 P65f/+, 8 P65+/ΔEC, 
P65,Opa1f/+, Opa1f/+ and Opa1+/ΔEC, 12 P65,Opa1+/ΔEC mice.  
(M) Photographs of representative melanomas removed after 16 days from 
subcutaneous implants of 5x104 B16F10 cells in 6-week-old mice of the indicated 
genotype. Mice were treated where indicated with MYLS22 or DMSO (10mg/kg) by 
peritumoral injection in sunflower oil (final V: 50 µl) every two days from day 10. Scale 
bar: 0.5 cm.  
(N) Growth curves of subcutaneously implanted B16F10 (5x104) tumors in 6-week-old 
mice of the indicated genotype treated as indicated. n=5 mice/group. *: p<0.05. 
 
Figure 6: EC Opa1 deletion impairs tumor metastatization 
(A) Photographs of lungs containing metastases from tail vein injected melanomas. 
Eleven days before mice were euthanized, organs explanted and images acquired, 
B16F10 (50x103) cells injected in the tail vein in 6-week-old mice of the indicated 
genotype. Scale bar: 1 cm.  
(B) Quantification of macro-metastases in lung. Experiments were performed as in (A). 
*p<0.0005, n=6 Opa1f/+ and 8 Opa1+/ΔEC mice.  
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(C) Photographs of representative 6-week-old mice of the indicated genotype 14 days 
after the injection of 1x105 melanoma B16F10 cells in the footpad.  
(D) Growth curves of footpad implanted 1x105 B16F10 melanomas at day 0 in 6-week-
old mice of the indicated genotype. n=14 Opa1f/+ and 8 Opa1+/ΔEC mice. *: p<0.05.  
(E) Photographs of representative sentinel popliteal lymph nodes explanted from mice 
of the indicated genotype in experiments as in A. Metastases of B16F10 melanomas 
are visible as dark masses. Scale bar: 0.5 cm.  
(F) Photographs of representative 6-week-old mice of the indicated genotype 14 days 
after the injection of 1x105 melanoma B16F10 cells into the footpad.  
(G) Growth curves of footpad implanted 1x105 B16F10 melanomas at day 0 in 6-week-
old mice of the indicated genotype. n=14 Opa1f/+ and 8 Opa1i ΔEC mice. *: p<0.05.  
(H) Photographs of representative sentinel popliteal lymph nodes explanted from mice 
of the indicated genotype in experiments as in E. Metastases of B16F10 melanomas 
are visible as dark masses. Scale bar: 0.5 cm. 
(I) Representative confocal images of CD31 (red) and DAPI (blue) immunofluorescence 
showing blood vessels in B16F10 melanomas from experiments as in F. Note the DAPI+ 
melanoma cells in the tumor vessels of Opa1f/+ but not of Opa1i ΔEC mice.  
(J) Representative confocal images of CD31 immunofluorescence (red) in melanomas 
explanted from the footpad of mice of the indicated genotype 16 days after the injection 
of 5x104 B16F10 cells. Scale bar: 100 µm.  
(K-M) Quantification of number of tumor blood vessels per field (K), tumor blood vessels 
diameter (L) and tumor blood vessels surface per field (M) in experiments as in F. *: 
p=0.002 in (L) and p=8x10-6 in (M). n=14 Opa1f/f and 8 Opa1iΔEC mice.  
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(N) Representative confocal images of Hoechst (nuclei, blue) CD31 (endothelial marker, 
green) and SMA (pericyte marker, red) immunofluorescence in experiments as in F. 
Scale bar: 250 µm. 
(O) Photographs of ears of 6-week-old mice of the indicated genotype 30 days after the 
injection of 5x105 melanoma B16F10 cells. Scale bar: 0.5 cm.  
(P) Quantification of tumor size in the ear. Experiment was performed as in (I). n=11 
Opa1f/+ and 8 Opa1+/ΔEC mice.  
(Q) Photographs of representative sentinel cervical lymph nodes explanted from mice of 
the indicated genotype in experiments as in (I). Metastases of B16F10 melanomas are 
visible as dark masses. Scale bar: 0.5 cm.  
 
Fig 1 Click here to access/download;Figure;Figure 1.tif
Fig 2 Click here to access/download;Figure;Figure 2.tif
Fig 3 Click here to access/download;Figure;Figure 3.tif
Fig 4 Click here to access/download;Figure;Figure 4.tif
Fig 5 Click here to access/download;Figure;Figure 5.tif
Fig 6 Click here to access/download;Figure;Figure 6.tif
1 
 
Developmental and tumour angiogenesis requires the mitochondria-shaping 
protein Opa1. 
 
Herkenne et al. 
 
 
 
Supplementary online material 
 
 
 
Supplemental Text and Figures
2 
 
Supplementary Figures 
3 
 
 
Supplementary Figure 1: OPA1 but not mitofusins silencing affects angiogenesis in HUVEC, 
related to Fig. 2 
(A) Equal amounts of protein from HUVEC transfected for 48h as indicated were separated by SDS-
PAGE and immunoblotted with the indicated antibodies.  
(B) Representative confocal images of mitochondrial morphology in HUVEC transfected 48h as indicated 
as indicated and stained for TOM20.  
(C) Quantification of mitochondrial length in HUVEC transfected for 48h with indicated siRNA. Each dot 
represents 1 mitochondrion. *: p=3x10-18. n=3.  
(D) Quantification of cell death determined by Annexin/PI staining in HUVEC transfected for 48h with 
indicated siRNA. n=4.  
(E) Representative brightfield images of HUVEC transfected with the indicated siRNA for 48h in a scratch-
wound assay. Scale bar: 100µm.  
(F) Quantification of cellular migration determined by scratch wound assay at 6h in experiments as in E. 
∗p=5x10-6, n=12.  
(G) Quantification of cellular proliferation determined by measuring BrdU incorporation after 24h in 
HUVEC transfected for 48h with indicated siRNA. ∗p=3x10-5, n=7. 
(H) Representative brightfield images of endothelial tubular network of HUVEC transfected with the 
indicated siRNA seeded on Matrigel for 6h. Scale bar: 250 µm.  
(I) Quantification of branching points (black) and tube length (blue) in experiments as in H. *: p=1x10-5 
(number), p=2x10-6 (length). n=10. 
(J) Equal amounts of protein extracted from HUVEC transfected 48h with the indicated siRNA were 
separated by SDS-PAGE and immunoblotted with the indicated antibodies. 
(K) Representative confocal images of mitochondrial morphology in HUVEC transfected for 48h with the 
indicated siRNA and stained for TOM20. Scale bar: 30 µm.  
(L) Quantification of mitochondrial length in experiments as in K. Each dot represents 1 mitochondrion. *: 
p=1x10-21 UNREL vs MFN1; p=4x10-19 UNREL vs MFN2. n=3.  
(M) Quantification of cell death determined by Annexin/PI staining in HUVEC transfected for 48h with 
indicated siRNA. n=4. *: p=1x10-4. 
4 
 
(N) Representative brightfield images of a scratch wound assay with HUVEC transfected for 48h with the 
indicated siRNA. Scale bar: 100 µm.  
(O) Quantification of cellular migration at 6h in a scratch wound assay in experiments as in N. n=4.  
(P) quantification of cellular proliferation determined by measuring BrdU incorporation after 24h in 
HUVEC transfected for 48h with indicated siRNA. n=4.  
(Q) Representative brightfield images of endothelial tubular network of HUVEC transfected with the 
indicated siRNA seeded on Matrigel for 6h. Scale bar: 250 µm.  
(R) Quantification of branching points (black) and tube length (blue) in experiments as in Q. n=4. 
5 
 
 
Supplementary Figure 2: OPA1 but not MFN1 ablation affects retinal venous vascularization, 
related to Fig. 3 
(A) Equal amounts of protein MPEC isolated from Opa1tg mice were separated by SDS-PAGE and 
immunoblotted with the indicated antibodies.  
(B) FACS analysis of cultured MPECs labelled with antibodies for endothelial-specific markers as 
indicated, followed by Fluorescein isothiocyanate-conjugated secondary antibody. Green line indicates 
secondary antibody, blue line indicates anti-VE-cadherin, anti-VEGFR2 or anti-ESM1-specific-IgG.  
(C) Equal amounts of protein from MPEC isolated from mice of the indicated genotype were separated by 
SDS-PAGE and immunoblotted with the indicated antibodies.  
(D) Representative isolectin b4 immunofluorescence (magnification 5x) of flat-mounted retinas from 6-
day-old pups of the indicated genotype showing a vein. Scale bar: 100 µm.  
(E) Quantification of total venous branching points/mm of vein. Experiments were performed as in (D). *: 
p=0.0002, n=12 Opa1f/+ and 13 Opa1+/ΔEC mice.  
(F) Representative isolectin b4 immunofluorescence (magnification 5x) of flat-mounted retinas from 6-
day-old pups of the indicated genotype. Blue box: proximal vein (Vp); yellow box: central vein (Vc); green 
box: distal vein (Vd). Scale bar: 250 µm.  
(G) Quantification of proximal, central and distal venous branching points. Experiments were performed 
as in (F). *: p=9x10-5 Opa1f/+ vs. Opa1+/ΔEC Vd. n=12 Opa1f/+ and 15 Opa1+/ΔEC mice.  
(H) Representative isolectin b4 immunofluorescence (magnification 5x) of flat-mounted retinas from 6-
day-old pups of the indicated genotype. Artery is indicated with A. Scale bar: 100 µm.  
(I) Quantification of total arterial branching points. Experiments were performed as in (H). n=15 
mice/genotype.  
(J) 2Δct of Opa1 mRNA levels determined by RT-PCR in MPECs isolated from 5-day-old pups injected 
with tamoxifen from P1 to P3. *: p=0.0003, n=9 mice per genotype.  
(K) Representative confocal images of flat-mounted retinas from 6-day-old pups of the indicated 
genotype, stained for OPA1 (green) and isolectin b4 (red). Scale bar: 250 µm.  
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(L) Representative isolectin b4 immunofluorescence (magnification 5x) of flat-mounted retinas from 6-day-
old pups of the indicated genotype showing a vein. Scale bar: 100 µm.  
(M) Quantification of total venous branching points/mm of vein. Experiments were performed as in (L). *: 
p=0.004, n=12 Opa1f/f and 9 Opa1iΔEC mice.  
(N) Representative isolectin b4 immunofluorescence (magnification 5x) of flat-mounted retinas from 6-
day-old pups of the indicated genotype. Green box: distal vein (Vd), yellow box: central vein (Vc) and blue 
box: proximal vein (Vp). Scale bar: 100 µm.  
(O) Quantification of proximal, central and distal venous branching points. Experiments were performed 
as in (F) from 6-day-old pups of the indicated genotype. *: p=2x10-5 Opa1f/f vs. Opa1iΔEC Vd. n=13 Opa1f/f 
and 10 Opa1iΔEC mice. 
(P) Representative isolectin b4 immunofluorescence (magnification 5x) of flat-mounted retinas from 6-
day-old pups of the indicated genotype showing an artery. Scale bar: 100 µm. 
(Q) Quantification of total arterial branching points. Experiments were performed as in (P). n=11 
mice/genotype  
(R) Representative isolectin b4 immunofluorescence (magnification 2.5x) of flat-mounted retinas from 6-
day-old pups of the indicated genotype. a (red) indicates the vascular front radius and b (yellow) the 
retinal radius. Scale bar: 50µm.  
(S) Quantification of radial expansion calculated by the ratio a/b in experiments as in (R). n=8 Mfn1f/f and 
6 Mfn1iΔEC mice.  
(T) Representative isolectin-b4 immunofluorescence (magnification 5x) of flat-mounted retinas from 6-
day-old pups of the indicated genotype. Scale bar: 100 µm.  
(U) Quantification of branching points/mm2 of retina in experiments as in T, n=8 Mfn1f/f and 6 Mfn1iΔEC 
mice.  
(V) Representative isolectin b4 immunofluorescence (magnification 40x) of flat-mounted retinas from 6-
day-old pups of the indicated genotype. Red arrows: tips cells. Scale bar: 20 µm.  
(W) Quantification of number of tip cells in experiments as in (V). n=8 Mfn1f/f and 6 Mfn1iΔEC mice. 
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Supplementary Figure 3: OPA1 and MICU1 affect NF B activation in HUVECs, related to Fig. 4 
(A) HUVEC pretreated for 1h where indicated with PD98059, U0126, Wortmaninn or for 3h with LLL12 or 
AG490 and were treated where indicated with VEGF for 1h. Equal amounts of protein were separated by 
SDS-PAGE and immunoblotted with the indicated antibodies.  
(B) Representative confocal images of mitochondrial morphology in HUVEC treated as indicated and 
stained for TOM20. Scale bar: 30 µm. 
(C) Quantification of mitochondria length in experiments as in B. Each dot represents 1 mitochondrion. *: 
p=4x10-14 vehicle vs. vehicle+VEGF; p=2X10-15 wortmannin vs wortmannin+VEGF. n=3 independent 
experiments. 
(D) PCR analysis of genomic DNA from MPEC isolated from Opa1f/f::Opa1tg mice infected with the 
indicated adenoviruses. 
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(E) 2Δct of OPA1mRNA levels determined by RT-PCR in Opa1f/f::Opa1tg MPEC infected with the indicated 
adenovirus and treated for 1 h as indicated.*: p<0.05, n=4. 
(F) Representative confocal images of mitochondrial morphology in Opa1f/f::Opa1tg MPEC infected with 
the indicated adenovirus, treated for 2h as indicated. and stained for TOM20. Scale bar: 30 µm. 
(G) Quantification of mitochondria length in experiments as in F. Each dot represents 1 mitochondrion. *: 
p=5X10-6. n=3. 
(H) OCR in HUVEC transfected as indicated for 48h. Where indicated, oligomycin (Oligo, 0.1μM), 
carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP, 1μM), rotenone (Rot, 0.5μM), and antimycin 
A (AA, 0.5μM) were injected.  
(I) Flow cytometric quantification of TMRM fluorescence in HUVEC transfected for 48h with the indicated 
siRNA and treated as indicated. n=4.  
(J, K) Equal amounts of protein extracted from HUVEC transfected for 48h with the indicated siRNA were 
separated by SDS-PAGE and immunoblotted with the indicated antibodies.  
(L) Representative brightfield images of a scratch-wound assay with HUVEC transfected with the 
indicated siRNA for 48h. Scale bar: 100µm.  
(M) Quantification of cellular migration at 6h in scratch wound assay experiments as in L. *: p<0.05, n=6.  
(N) Representative brightfield images of endothelial tubular network HUVEC transfected with the 
indicated siRNA seeded on Matrigel for 6h. Scale bar: 250 µm.  
(O, P) Quantification of branching points (O) and tube length (P) in experiments as in N. *: p<0.05, n=5.  
(Q) Quantification of cellular proliferation determined by BrdU incorporation after 24h in HUVEC 
transfected for 48h with the indicated siRNA. *: p<0.05, n=5. 
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Supplementary Figure 4: OPA1 ablation impairs angiogenesis by activating the NF B pathway, 
related to Fig. 4 
(A) P65 DNA-binding ability determined by ELISA on equal amounts of proteins from HUVEC transfected 
48h with the indicated siRNA and treated for 6h as indicated. *: p=2x10-7 UNREL-DMSO vs OPA1-DMSO; 
#: p=8x10-7 OPA1-DMSO versus OPA1-BAY11-7082; n=8.  
(B) Quantification of cellular migration determined at 6h in a scratch wound assay of HUVEC transfected 
for 48h with the indicated siRNA and treated for 6h as indicated. *: p =0.0006 UNREL-DMSO vs OPA1-
DMSO; #: p=0.009 OPA1-DMSO vs OPA1-BAY11-7082; n=9. 
(C) Equal amounts of protein from HUVEC transfected for 48h with the indicated siRNA were separated 
by SDS-PAGE and immunoblotted with the indicated antibodies.  
(D-F) Opa1 (D), P65 (E) and Cre (F) RT-PCR analysis of transcripts in mice of the indicated genotype. 
(G) Equal amounts of protein (20µg) from MPEC isolated from mice of the indicated genotype were 
separated by SDS-PAGE and immunoblotted with the indicated antibodies.  
(H) P65 DNA-binding ability determined by ELISA on equal amounts of protein from Zebrafish injected 
with the indicated morpholinos and treated for 6h as indicated. *: p=4x10-6 unrel-DMSO vs. opa1-DMSO; 
#: p=2x10-7 opa1-DMSO vs. opa1-BAY11-7082; n=4. 
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Supplementary Figure 5: Endothelial Opa1 but not Mfn1 ablation impairs tumor growth, related to 
Fig. 5  
(A) Photographs of representative breast adenocarcinoma removed after 16 days from subcutaneous 
implants of 1.5x105 E0771 cells in 6-week-old mice of the indicated genotype. Scale bar: 0.2 cm.  
(B) Growth curves of 5x104 B16F10 melanoma cells subcutaneously implanted at day 0 in 6-week-old 
mice of the indicated genotype. n=7 Opa1f/+ and 6 Opa1+/ΔEC mice. *: p<0.05.  
(C) B16F10 melanomas in experiments as in Figure 5B were removed at day 16, stained with CD31 for 
blood vessels and number of tumor blood vessels was quantified. n=7 Opa1f/+ and 9 Opa1+/ΔEC mice.  
(D) Percentage of myeloid cells determined by flow cytometry in 500 mm3 melanomas from 5x104 B16F10 
cells implanted subcutaneously in 6-week-old mice of the indicated genotype, n=4 mice/genotype. 
(E) 2Δct of OPA1 mRNA levels determined by RT-PCR in MPECs isolated from 6-week-old mice injected 
with tamoxifen between P15 and P20. ∗p=0.01 Opa1f/+ vs Opa1+/iΔEC; **: p=0.0009 Opa1f/f vs Opa1iΔEC; 
n=7 Opa1f/f and Opa1iΔEC/+, 6 Opa1iΔEC. 
(F) Quantification of number of tumor blood vessels in experiments as in Figure 5F-G performed on mice 
of the indicated genotype. n=8 Opa1f/f and 9 Opa1iΔEC.  
(G) 2Δct of Mfn1 mRNA levels determined by RT-PCR in MPECs isolated from 6-week-old mice injected 
with tamoxifen between P15 and P30. *: p=1x10-5, n=7 mice/genotype.  
(H) Photographs of representative melanomas removed after 16 days from subcutaneous implants of 
5x104 B16F10 cells in 6-week-old mice of the indicated genotype. Scale bar: 0.5 cm  
(I) Growth curves of subcutaneously implanted 5x104 B16F10 melanomas at day 0 in 6-week-old mice of 
the indicated genotype. n=7 mice/genotype.  
(J) Representative confocal images of B16F10 melanomas in experiments as in Figure 5K-L stained with 
Hoechst (blue) and CD31 (red) to label blood vessels. Scale bar: 200 µm. 
11 
 
(K-M) Quantification of number of tumor vessels number (K), diameter (L) and surface (M) in experiments 
as in J. *: p=1x10-5 Opa1f/+ vs. Opa1+/ΔEC: #: p=0.05 Opa1+/ΔEC vs P65,Opa1+/ΔEC in (L). *: p =0.002 Opa1f/+ 
vs. Opa1+/ΔEC; #: p=0.007 Opa1+/ΔEC vs. P65,Opa1+/ΔEC in (M). n=7 mice/genotype. 
(N) Chemical formula of the Opa1 inhibitor N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-YL)-
3-methyl-1-PH+ (MYLS22). 
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Supplementary Figure 6: OPA1 ablation impairs lymphangiogenesis, related to Fig. 6 
(A) Representative pictures of 6-week-old mice of the indicated genotype mice 16h after Evan's blue 
intradermal ear injection.  
(B) Quantification of Evan's blue dye in ear skin in experiments were performed as in (A). *: p=2x10-5, 
n=50 Opa1f/+ and 37 Opa1+/ΔEC mice.  
(C) Representative confocal images of trunk venous and lymphatic vessels of Zebrafish Tg (stab1:YFP) 5 
days after the injection of the indicated morpholino. LV: lymphatic vessels. Scale bar: 150 µm.  
(D) Representative brightfield images of a scratch-wound assay of HMVEC-dly transfected for 48h with 
the indicated siRNA. Scale bar: 100 µm.  
(E) Quantification of cellular migration at6 h in experiments as in (D). *: p=0.003, n=4  
(F) Representative brightfield images of the lymphatic tubular network of HMVEC-dly transfected for 48h 
with the indicated siRNA and seeded on Matrigel for 6h. Scale bar: 250 µm.  
(G) Quantification of tube length in experiments as in (F). *: p=4x10-13, n=25.  
(H) Quantification of branching points in experiments as in (F). *: p=3x10-5, n=6.  
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(I) Quantification of cellular proliferation determined by measuring BrdU incorporation after 24h in 
HMVEC-dly transfected for 48h with the indicated siRNA. n=4. 
(J) Average±SEM of 4 independent RT-PCR analyses of the indicated genes in HMVEC-dly transfected 
32h with OPA1 siRNA, normalized to a non-related human sequence (UNREL) siRNA. *: p<0.05.  
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Supplementary Tables  
 
Primers for human genes (qPCR) Sequence 5'-3' 
hs PODOPLANIN for  GTGTAACAGGCATTCGCATCG 
hs PODOPLANIN rev TGTGGCGCTTGGACTTTGT 
hs PROX1 for AAAGTCAAATGTACTCCGCAAGC 
hs PROX1 rev  CTGGGAAATTATGGTTGCTCCT 
hs LYVE1 for  AATTTCACAGAAGCTAAGGAGGC 
hs LYVE1 rev  TCAAGGCTGTTTCAACTTGGTC 
hs NRP2 for  CCCTCACTTTGAAATCGAGAAGC 
hs NRP2 rev  CTGCGGATTCACTGTCCCC 
hsVEGFR3 for TGCAAGAGGAAGAGGAGGTCT 
hsVEGFR3 rev  CAGGCTTGGCGGGCTGTCC 
hs OPA1 for  CGACCCCAATTAAGGACATCC 
hs OPA1rev GCGAGGCTGGTAGCCATATTT 
hs DRP1 for  CACCCGGAGACCTCTCATTC 
hs DRP1 rev  CCCCATTCTTCTGCTTCCAC 
hs MFN1 for  ATGACCTGGTGTTAGTAGACAGT 
hs MFN1 rev AGACATCAGCATCTAGGCAAAAC 
hs MFN2 for  CACATGGAGCGTTGTACCAG 
hs MFN2 rev  TTGAGCACCTCCTTAGCAGAC 
hs VEGFa for  CTCTACCTCCACCATGCCAAGT 
hs VEGFa rev  TGCGCTGATAGACATCCATGA 
hs SERPIN for  CATGCCCTTGTCATCAATCTTG 
hs SERPIN rev  CATGCCCTTGTCATCAATCTTG 
hs PDGFb for  AACAACCGCAACGTGCAGT 
hs PDGFb rev  GTCACCGTGGCCTTCTTAAAGA 
hs EPHRINb2 for  CGTGCTGGAGAATTGACTGA 
hs EHRINb2 rev  CTGTCTTCCCTTGGCTTCTG 
hs EPHRIN b4 rev  TTGATTGCCACACAGCTCTC 
hs EPHRIN b4 for  GGTCTACATCGACCCCTTCA 
hs CDH5 for  ATGAGAATGACAATGCCCCG 
hs CDH5 rev  TGTCTATTGCGGAGATCTGCAG 
hs FGFR for  ATAAAAAGACAACCAACGGCCG 
hs FGFR rev ACCCCGAAAGACCACACATCA 
hs PPIA for  CCAACACAAATGGTTCCCAGT 
hs PPIA rev  CCATGGCCTCCACAATATTCA 
hs β-2MiCROGLOBULINrev  AATCCAAATGCGGCATCT 
hs β 2MiCROGLOBULIN for  GAGTATGCCTGCCGTGTG 
 
Table S1: List of oligonucleotides used for human QRT-PCR (related to key 
resources table) 
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Primers for murine genes (qPCR) Sequence 5'-3' 
mm opa1for ATACTGGGATCTGCTGTTGG 
mm opa1 rev  AAGTCAGGCACAATCCACTT 
Mm actin for ACGGCCAGGTCATCACTATTG 
Mm actin rev AGGAAGGCTGGAAAAGAGCC 
 
Table S2: List of oligonucleotides used for mouse QRT-PCR (related to key 
resources table) 
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Allele Sequences 5'-3' 
mito ec gfp for  TCTTCTTCAAGGACGACGGCAACT 
mito ec gfp rev  CCTTGATGCCGTTCTTCTGCTTGT 
Opa1f/f for  CAGTGTTGATGACAGCTCAG 
Opa1f/f rev  CATCACACACTAGCTTACATTTGC 
cre for GCGGTCTGGCAGTAAAAACTATC 
cre rev  GTGAAACAGCATTGCTGTCACTT 
P65f/f for  GAGCGCATGCCTAGCACCAG 
P65f/f rev  GTGCACTGCATGCGTGCAG 
 
Table S3: List of oligonucleotides used for mouse genotyping (related to key 
resources table) 
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Supplementary datasets 
Dataset 1. Pathways modified in HUVEC treated with VEGF for 1, 4 and 12h. 
The list was generated from the transcriptional changed genes from ANGIOGENES 
database of RNA sequencing analyzed by SPIA. 
 
Dataset 2. Differentially expressed genes upon Opa1 silencing in HUVEC 
The list was obtained from triplicates analyses of control and Opa1-ablated HUVECs 
(fold change threshold=0.6 FDR=0.05). Raw sequenced reads were aligned by using 
STAR (reference genome HOMO SAPIENS UCSChg19). Fold change was calculated 
using DESeq2 (v. 1.6.3). 
 
  
Supplemental dataset 1
Click here to access/download
Supplemental Videos and Spreadsheets
supplementary dataset 1.xlsx
  
Supplemental dataset 2
Click here to access/download
Supplemental Videos and Spreadsheets
supplementary dataset 2.xlsx
